Revision as of 23:40, 9 February 2023

Note: these are regimens tested in histology-specific populations, please see the main thyroid cancer page for other regimens.

0 regimens on this page 0 variants on this page

Guidelines

ATA

2015: Guidelines for the management of medullary thyroid carcinoma PubMed

ESMO

2019: Filetti et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Older

2012: Pacini et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up PubMed

NCCN

NCCN Guidelines - Thyroid Carcinoma

All lines of therapy

Cabozantinib monotherapy

Regimen

Study	Years of enrollment	Evidence	Comparator	Comparative Efficacy
Kurzrock et al. 2011 (XL184-001)	2005-2008	Non-randomized
Elisei et al. 2013 (EXAM)	2008-2011	Phase 3 (E-RT-esc)	Placebo	Superior PFS Median PFS: 11.2 vs 4 mo (HR 0.28, 95% CI 0.19-0.40)

Note: To be taken at least 2 hours before or 1 hour after meals.

Targeted therapy

Cabozantinib (Cometriq) 140 mg PO once per day

Continued indefinitely

References

XL184-001: Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Müller T, Ratain MJ, Salgia R. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 1;29(19):2660-6. Epub 2011 May 23. link to original article contains dosing details in manuscript link to PMC article PubMed NCT00215605
EXAM: Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013 Oct 10;31(29):3639-46. Epub 2013 Sep 3. Erratum in: J Clin Oncol. 2014 Jun 10;32(17):1864. link to original article contains dosing details in manuscript link to PMC article PubMed NCT00704730
1. Update: Schlumberger M, Elisei R, Müller S, Schöffski P, Brose M, Shah M, Licitra L, Krajewska J, Kreissl MC, Niederle B, Cohen EEW, Wirth L, Ali H, Clary DO, Yaron Y, Mangeshkar M, Ball D, Nelkin B, Sherman S. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. Ann Oncol. 2017 Nov 1;28(11):2813-2819. link to original article link to PMC article PubMed

Placebo

Regimen

Study	Years of enrollment	Evidence	Comparator	Comparative Efficacy
Wells et al. 2011 (ZETA)	2006-2007	Phase 3 (C)	Vandetanib	Inferior PFS
Elisei et al. 2013 (EXAM)	2008-2011	Phase 3 (C)	Cabozantinib	Inferior PFS

No active antineoplastic treatment. Included for reference purposes only.

References

ZETA: Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012 Jan 10;30(2):134-41. Epub 2011 Oct 24. link to original article contains dosing details in manuscript link to PMC article PubMed NCT00410761
EXAM: Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013 Oct 10;31(29):3639-46. Epub 2013 Sep 3. Erratum in: J Clin Oncol. 2014 Jun 10;32(17):1864. link to original article contains dosing details in manuscript link to PMC article PubMed NCT00704730

Sorafenib monotherapy

Regimen

Study	Years of enrollment	Evidence
Lam et al. 2010 (OSU 06054)	2006-2008	Phase 2

Targeted therapy

Sorafenib (Nexavar) 400 mg PO twice per day

Continued indefinitely

References

OSU 06054: Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely PE Jr, Vasko VV, Saji M, Snyder PJ, Wei L, Arbogast D, Collamore M, Wright JJ, Moley JF, Villalona-Calero MA, Shah MH. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol. 2010 May 10;28(14):2323-30. Epub 2010 Apr 5. link to original article contains dosing details in manuscript link to PMC article PubMed NCT00390325

Sunitinib monotherapy

Regimen

Study	Years of enrollment	Evidence
Carr et al. 2010	2007-2009	Phase 2

Targeted therapy

Sunitinib (Sutent) 37.5 mg PO once per day

Continued indefinitely

References

Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010 Nov 1;16(21):5260-8. Epub 2010 Sep 16. link to original article contains dosing details in manuscript link to PMC article PubMed

Vandetanib monotherapy

Regimen variant #1, 100 mg/day

Study	Years of enrollment	Evidence
Robinson et al. 2010 (D4200C00068)	2006-2007	Phase 2, <20 patients

Targeted therapy

Vandetanib (Caprelsa) 100 mg PO once per day

Continued indefinitely

Subsequent treatment

At progression, eligible patients could increase the dose to 300 mg PO once per day; see paper for details

Regimen variant #2, 300 mg/day

Study	Years of enrollment	Evidence	Comparator	Comparative Efficacy
Wells et al. 2010	2004-2006	Phase 2
Wells et al. 2011 (ZETA)	2006-2007	Phase 3 (E-RT-esc)	Placebo	Superior PFS Median PFS: NYR vs 19.3 mo (HR 0.46, 95% CI 0.31-0.69)

Targeted therapy

Vandetanib (Caprelsa) 300 mg PO once per day

Continued indefinitely

References

Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J, Schlumberger M. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2010 Feb 10;28(5):767-72. Epub 2010 Jan 11. link to original article contains dosing details in manuscript link to PMC article PubMed
D4200C00068: Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 2010 Jun;95(6):2664-71. Epub 2010 Apr 6. link to original article contains dosing details in manuscript link to PMC article PubMed content property of HemOnc.org NCT00358956
ZETA: Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012 Jan 10;30(2):134-41. Epub 2011 Oct 24. link to original article contains dosing details in manuscript link to PMC article PubMed NCT00410761

Advanced or metastatic disease

Axitinib monotherapy

Regimen

Study	Years of enrollment	Evidence
Locati et al. 2014 (A4061027)	2006-2008	Phase 2

Targeted therapy

Axitinib (Inlyta) 5 mg PO twice per day

Continued indefinitely

References

A4061027: Locati LD, Licitra L, Agate L, Ou SH, Boucher A, Jarzab B, Qin S, Kane MA, Wirth LJ, Chen C, Kim S, Ingrosso A, Pithavala YK, Bycott P, Cohen EE. Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments. Cancer. 2014 Sep 1;120(17):2694-703. Epub 2014 May 20. link to original article contains dosing details in manuscript PubMed NCT00389441

Sunitinib monotherapy

Regimen

Study	Years of enrollment	Evidence	Efficacy
Carr et al. 2010	2007-2009	Phase 2	ORR: 31% (95% CI: 16-47)

Targeted therapy

Sunitinib (Sutent) 37.5 mg PO once per day

Continued indefinitely

References

Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010 Nov 1;16(21):5260-8. Epub 2010 Sep 16. link to original article contains dosing details in manuscript link to PMC article PubMed

@@ Line 3: / Line 3: @@
 [[#top|Back to Top]]
 </div>
-The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp NCCN Guidelines]. Is there a regimen missing from this list? See the [[Non-small_cell_lung_cancer|main NSCLC page]] for current regimens.
+{{#lst:Section editor transclusions|endo}}
+<div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px">
+[[#top|Back to Top]]
+</div>
+Note: these are regimens tested in histology-specific populations, please see the '''[[Thyroid cancer|main thyroid cancer page]]''' for other regimens.
 {| class="wikitable" style="float:right; margin-right: 5px;"
 |-
-|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]]  |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
+|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
-<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]]  |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
+<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
 |}
 {{TOC limit|limit=3}}
-=Neoadjuvant therapy=
+=Guidelines=
-==MIC {{#subobject:6be6b3|Regimen=1}}==
+==[https://www.thyroid.org/ ATA]==
-MIC: '''<u>M</u>'''itomycin, '''<u>I</u>'''fosfamide, '''<u>C</u>'''isplatin
+*'''2015:''' Guidelines for the management of medullary thyroid carcinoma [https://pubmed.ncbi.nlm.nih.gov/27118126 PubMed]
+==[http://www.esmo.org/ ESMO]==
+*'''2019:''' Filetti et al. [https://doi.org/10.1093/annonc/mdz400 Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up]
+===Older===
+*'''2012:''' Pacini et al. [http://annonc.oxfordjournals.org/content/23/suppl_7/vii110.full.pdf+html Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/22997443 PubMed]
+==[https://www.nccn.org/ NCCN]==
+*[https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf NCCN Guidelines - Thyroid Carcinoma]
+=All lines of therapy=
+==Cabozantinib monotherapy {{#subobject:1d67e4|Regimen=1}}==
 <div class="toccolours" style="background-color:#eeeeee">
-===Regimen {{#subobject:c1b1e|Variant=1}}===
+===Regimen {{#subobject:d4c2dd|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 !style="width: 20%"|Study
@@ Line 22: / Line 34: @@
 !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 |-
-|[https://doi.org/10.1056/NEJM199401203300301 Rosell et al. 1994]
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646303/ Kurzrock et al. 2011 (XL184-001)]
-|1989-1991
+|2005-2008
-|style="background-color:#1a9851"|Phase 3 (E-esc)
+| style="background-color:#91cf61" |Non-randomized
-|[[Non-small_cell_lung_cancer_-_null_regimens#No_neoadjuvant_therapy|No preoperative therapy]]
-| style="background-color:#1a9850" |Superior OS
-|-
-|[https://doi.org/10.1200/JCO.2002.20.1.247 Depierre et al. 2002]
-|1991-1997
-|style="background-color:#1a9851"|Phase 3 (E-esc)
-|[[Non-small_cell_lung_cancer_-_null_regimens#No_neoadjuvant_therapy|No preoperative therapy]]
-| style="background-color:#ffffbf" |Seems not superior
-|-
-|}
-<div class="toccolours" style="background-color:#b3e2cd">
-====Chemotherapy====
-*[[Mitomycin (Mutamycin)]] 6 mg/m<sup>2</sup> IV once on day 1
-*[[Ifosfamide (Ifex)]] 3000 mg/m<sup>2</sup> IV over 3 hours once on day 1
-*[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV over 60 minutes once on day 1
-====Supportive therapy====
-*[[Mesna (Mesnex)]] 1000 mg/m<sup>2</sup> IV over 3 hours once on day 1, '''admixed with ifosfamide'''
-*[[Metoclopramide (Reglan)]] 3 mg/kg IV, given 30 minutes prior and 90 minutes after chemotherapy
-*[[Dexamethasone (Decadron)]] 20 mg IV once, given 30 minutes prior to chemotherapy
-'''21-day cycle for 3 cycles'''
-</div>
-<div class="toccolours" style="background-color:#cbd5e7">
-====Subsequent treatment====
-*[[Surgery#Lung_cancer_surgery|Surgery]]
-</div></div>
-===References===
-# Rosell R, Gómez-Codina J, Camps C, Maestre J, Padille J, Cantó A, Mate JL, Li S, Roig J, Olazábal A, Canela M, Ariza A, Skacel Z, Morera-Prat J, Abad A. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 1994 Jan 20;330(3):153-8. [https://doi.org/10.1056/NEJM199401203300301 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/8043059 PubMed]
-# Depierre A, Milleron B, Moro-Sibilot D, Chevret S, Quoix E, Lebeau B, Braun D, Breton JL, Lemarié E, Gouva S, Paillot N, Bréchot JM, Janicot H, Lebas FX, Terrioux P, Clavier J, Foucher P, Monchâtre M, Coëtmeur D, Level MC, Leclerc P, Blanchon F, Rodier JM, Thiberville L, Villeneuve A, Westeel V, Chastang C; IFCT. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol. 2002 Jan 1;20(1):247-53. [https://doi.org/10.1200/JCO.2002.20.1.247 link to original article] [https://pubmed.ncbi.nlm.nih.gov/11773176 PubMed]
-=Adjuvant therapy=
-==Radiation therapy {{#subobject:743aa8|Regimen=1}}==
-RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
-<div class="toccolours" style="background-color:#eeeeee">
-===Regimen {{#subobject:426dfc|Variant=1}}===
-{| class="wikitable sortable" style="width: 100%; text-align:center;"
-!style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
-!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 20%"|Comparator
-!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
-|-
-|[https://doi.org/10.1056/nejm200010263431703 Keller et al. 2000 (ECOG E3590)]
-|1991-1997
-|style="background-color:#1a9851"|Phase 3 (C)
-|[[#Cisplatin_.26_Etoposide_.28EP.29_.26_RT|EP & RT]]
-|style="background-color:#ffffbf"|Did not meet endpoint of OS
-|-
-|}
-<div class="toccolours" style="background-color:#cbd5e8">
-====Preceding treatment====
-*Complete [[Surgery#Lung_cancer_surgery|surgical resection]]
-</div>
-<div class="toccolours" style="background-color:#b3e2cd">
-====Radiotherapy====
-*[[External_beam_radiotherapy|Radiation therapy]], 1.8 Gy fractions x 28 fractions (total dose: 50.4 Gy)
-'''5-week course'''
-</div></div>
-===References===
-# '''ECOG E3590:''' Keller SM, Adak S, Wagner H, Herskovic A, Komaki R, Brooks BJ, Perry MC, Livingston RB, Johnson DH; [[Study_Groups#ECOG|ECOG]]. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. N Engl J Med. 2000 Oct 26;343(17):1217-22. [https://doi.org/10.1056/nejm200010263431703 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/11071672 PubMed]
-=Induction therapy for locally advanced disease=
-==MIC {{#subobject:ebf0c1|Regimen=1}}==
-MIC: '''<u>M</u>'''itomycin, '''<u>I</u>'''fosfamide, '''<u>C</u>'''isplatin
-<br>MIP: '''<u>M</u>'''itomycin, '''<u>I</u>'''fosfamide, '''<u>P</u>'''latinol (Cisplatin)
-<div class="toccolours" style="background-color:#eeeeee">
-===Regimen {{#subobject:d1267e|Variant=1}}===
-{| class="wikitable sortable" style="width: 100%; text-align:center;"
-!style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
-!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 20%"|Comparator
-!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
-|-
-|[https://doi.org/10.1023/a:1008319506107 Sculier et al. 1999]
-|1989-1996
-| style="background-color:#91cf61" |Non-randomized portion of phase 3 RCT
 | style="background-color:#d3d3d3" |
 | style="background-color:#d3d3d3" |
 |-
-|[https://doi.org/10.1093/annonc/mdh105 Sculier et al. 2004]
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164813/ Elisei et al. 2013 (EXAM)]
-|1996-2002
+|2008-2011
-|style="background-color:#1a9851"|Phase 3 (C)
+| style="background-color:#1a9851" |Phase 3 (E-RT-esc)
-|[[#SuperMIP_99|SuperMIP]]
+|[[#Placebo_2|Placebo]]
-| style="background-color:#ffffbf" |Seems not superior
+| style="background-color:#1a9850" |Superior PFS<br>Median PFS: 11.2 vs 4 mo<br>(HR 0.28, 95% CI 0.19-0.40)
 |-
 |}
+''Note: To be taken at least 2 hours before or 1 hour after meals.''
 <div class="toccolours" style="background-color:#b3e2cd">
-====Chemotherapy====
+====Targeted therapy====
-*[[Mitomycin (Mutamycin)]]
+*[[Cabozantinib (Cometriq)]] 140 mg PO once per day
-*[[Ifosfamide (Ifex)]]
+'''Continued indefinitely'''
-*[[Cisplatin (Platinol)]]
-</div>
-<div class="toccolours" style="background-color:#cbd5e7">
-====Subsequent treatment====
-*Sculier et al. 1999: MIP x 3 versus [[Non-small_cell_lung_cancer#Radiation_therapy|RT]]
-*Sculier et al. 2004: [[Non-small_cell_lung_cancer#Radiation_therapy|RT]]
-</div></div>
-===References===
-# Sculier JP, Paesmans M, Lafitte JJ, Baumöhl J, Thiriaux J, van Cutsem O, Recloux P, Bureau G, Berchier MC, Zacharias C, Mommen P, Bosschaerts T, Berghmans T, van Houtte P, Ninane V, Klastersky J; European Lung Cancer Working Party. A randomised phase III trial comparing consolidation treatment with further chemotherapy to chest irradiation in patients with initially unresectable locoregional non-small-cell lung cancer responding to induction chemotherapy. Ann Oncol. 1999 Mar;10(3):295-303. [https://doi.org/10.1023/a:1008319506107 link to original article] [https://pubmed.ncbi.nlm.nih.gov/10355573 PubMed]
-# Sculier JP, Lafitte JJ, Berghmans T, Van Houtte P, Lecomte J, Thiriaux J, Efremidis A, Koumakis G, Giner V, Richez M, Corhay JL, Wackenier P, Lothaire P, Paesmans M, Mommen P, Ninane V; European Lung Cancer Working Party. A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer. Ann Oncol. 2004 Mar;15(3):399-409. [https://doi.org/10.1093/annonc/mdh105 link to original article] [https://pubmed.ncbi.nlm.nih.gov/14998841 PubMed]
-==PEV {{#subobject:ebf0c1|Regimen=1}}==
-PEV: '''<u>P</u>'''latinol (Cisplatin), '''<u>E</u>'''toposide, '''<u>V</u>'''inblastine
-<div class="toccolours" style="background-color:#eeeeee">
-===Regimen {{#subobject:d1267e|Variant=1}}===
-{| class="wikitable sortable" style="width: 100%; text-align:center;"
-!style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
-!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 20%"|Comparator
-!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
-|-
-|[https://doi.org/10.1097/00000421-200206000-00007 Kim et al. 2002]
-|1988-1992
-|style="background-color:#1a9851"|Phase 3 (E-esc)
-|[[Non-small_cell_lung_cancer_-_null_regimens#No_induction|No]] induction
-| style="background-color:#ffffbf" |Seems not superior
-|-
-|}
-<div class="toccolours" style="background-color:#b3e2cd">
-====Chemotherapy====
-*[[Cisplatin (Platinol)]]
-*[[Etoposide (Vepesid)]]
-*[[Vinblastine (Velban)]]
-</div>
-<div class="toccolours" style="background-color:#cbd5e7">
-====Subsequent treatment====
-*[[Non-small_cell_lung_cancer#Radiation_therapy|RT]]
-</div></div>
-===References===
-# Kim TY, Yang SH, Lee SH, Park YS, Im YH, Kang WK, Ha SH, Park CI, Heo DS, Bang YJ, Kim NK. A phase III randomized trial of combined chemoradiotherapy versus radiotherapy alone in locally advanced non-small-cell lung cancer. Am J Clin Oncol. 2002 Jun;25(3):238-43. [https://doi.org/10.1097/00000421-200206000-00007 link to original article] [https://pubmed.ncbi.nlm.nih.gov/12040280 PubMed]
-=Definitive therapy for locally advanced disease=
-==MVP & RT {{#subobject:10d15d|Regimen=1}}==
-MVP & RT: '''<u>M</u>'''itomycin, '''<u>V</u>'''indesine, '''<u>P</u>'''latinol (Cisplatin), '''<u>R</u>'''adiation '''<u>T</u>'''herapy
-<div class="toccolours" style="background-color:#eeeeee">
-===Regimen {{#subobject:8fd069|Variant=1}}===
-{| class="wikitable sortable" style="width: 100%; text-align:center;"
-!style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
-!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 20%"|Comparator
-!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
-|-
-|[https://doi.org/10.1200/JCO.1999.17.9.2692 Furuse et al. 1999 (JCOG9202)]
-|1992-1994
-|style="background-color:#1a9851"|Phase 3 (E-switch-ic)
-|[[#MVP_.28Vindesine.29_88|MVP]], then [[#Radiation_therapy_88|RT]]
-| style="background-color:#91cf60" |Seems to have superior OS
-|-
-|}
-<div class="toccolours" style="background-color:#b3e2cd">
-====Chemotherapy====
-*[[Mitomycin (Mutamycin)]]
-*[[Vindesine (Eldisine)]]
-*[[Cisplatin (Platinol)]]
-====Radiotherapy====
-*[[External beam radiotherapy]]
 </div></div>
 ===References===
-# '''JCOG9202:''' Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N, Ariyoshi Y. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999 Sep;17(9):2692-9. [https://doi.org/10.1200/JCO.1999.17.9.2692 link to original article] [https://pubmed.ncbi.nlm.nih.gov/10561343 PubMed]
+# '''XL184-001:''' Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Müller T, Ratain MJ, Salgia R. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 1;29(19):2660-6. Epub 2011 May 23. [https://doi.org/10.1200/jco.2010.32.4145 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646303/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/21606412 PubMed] NCT00215605
-=Consolidation or maintenance after definitive therapy for inoperable disease=
+# '''EXAM:''' Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013 Oct 10;31(29):3639-46. Epub 2013 Sep 3. Erratum in: J Clin Oncol. 2014 Jun 10;32(17):1864. [https://doi.org/10.1200/jco.2012.48.4659 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164813/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/24002501 PubMed] NCT00704730
-==Bacillus Calmette-Guérin (BCG) monotherapy==
+## '''Update:''' Schlumberger M, Elisei R, Müller S, Schöffski P, Brose M, Shah M, Licitra L, Krajewska J, Kreissl MC, Niederle B, Cohen EEW, Wirth L, Ali H, Clary DO, Yaron Y, Mangeshkar M, Ball D, Nelkin B, Sherman S. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. Ann Oncol. 2017 Nov 1;28(11):2813-2819. [https://doi.org/10.1093/annonc/mdx479 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834040/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/29045520 PubMed]
+==Placebo==
 <div class="toccolours" style="background-color:#eeeeee">
 ===Regimen===
@@ Line 193: / Line 67: @@
 !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 |-
-|[https://doi.org/10.1016/S0140-6736(76)90213-0 Pines 1976]
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3675689/ Wells et al. 2011 (ZETA)]
-|1970-1973
+|2006-2007
-|style="background-color:#1a9851"|Randomized (C)
-|[[Non-small_cell_lung_cancer#Observation_2|Observation]]
-| style="background-color:#91cf60" |Seems to have superior OS
-|-
-|}
-<div class="toccolours" style="background-color:#cbd5e8">
-====Preceding treatment====
-*[[Regimen_classes#Radiotherapy-based_regimen|RT]]
-</div>
-<div class="toccolours" style="background-color:#b3e2cd">
-====Immunotherapy====
-*[[Bacillus Calmette-Guérin (BCG)]]
-</div></div>
-===References===
-# Pines A. A 5-year controlled study of BCG and radiotherapy inoperable lung cancer. Lancet. 1976 Feb 21;1(7956):380-1. [https://doi.org/10.1016/S0140-6736(76)90213-0 link to original article] [https://pubmed.ncbi.nlm.nih.gov/55647 PubMed]
-=Advanced or metastatic disease, first-line=
-==CAMP {{#subobject:2d62ce|Regimen=1}}==
-CAMP: '''<u>C</u>'''yclophosphamide, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>M</u>'''ethotrexate, '''<u>P</u>'''rocarbazine
-<div class="toccolours" style="background-color:#eeeeee">
-===Regimen {{#subobject:f79237|Variant=1}}===
-{| class="wikitable" style="width: 40%; text-align:center;"
-!style="width: 25%"|Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
-|-
-|[https://jamanetwork.com/journals/jama/article-abstract/362874 Bitran et al. 1978]
-| style="background-color:#91cf61" |Non-randomized
-|-
-|}
-<div class="toccolours" style="background-color:#b3e2cd">
-====Chemotherapy====
-*[[Cyclophosphamide (Cytoxan)]]
-*[[Doxorubicin (Adriamycin)]]
-*[[Methotrexate (MTX)]]
-*[[Procarbazine (Matulane)]]
-</div></div>
-===References===
-# Bitran JD, Desser RK, DeMeester T, Golomb HM. Metastatic non-oat-cell bronchogenic carcinoma: therapy with cyclophosphamide, doxorubicin, methotrexate, and procarbazine (CAMP). JAMA. 1978 Dec 15;240(25):2743-6. [https://jamanetwork.com/journals/jama/article-abstract/362874 link to original article] [https://pubmed.ncbi.nlm.nih.gov/713008 PubMed]
-# '''ECOG E1581:''' Ruckdeschel JC, Finkelstein DM, Ettinger DS, Creech RH, Mason BA, Joss RA, Vogl S. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol. 1986 Jan;4(1):14-22. [https://doi.org/10.1200/JCO.1986.4.1.14 link to original article] [https://pubmed.ncbi.nlm.nih.gov/3510278 PubMed]
-==CAP (Platinol) {{#subobject:379e5f|Regimen=1}}==
-CAP: '''<u>C</u>'''yclophosphamide, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>P</u>'''latinol (Cisplatin)
-<div class="toccolours" style="background-color:#eeeeee">
-===Regimen {{#subobject:e7847b|Variant=1}}===
-{| class="wikitable sortable" style="width: 100%; text-align:center;"
-!style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
-!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 20%"|Comparator
-!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
-|-
-|[https://doi.org/10.1200/jco.1984.2.5.391 Robert et al. 1984]
-|1978-1981
 | style="background-color:#1a9851" |Phase 3 (C)
-|1. [[#Cyclophosphamide_.26_Doxorubicin_.28AC.29_99|Cyclophosphamide & Doxorubicin (AC)]]<br>2. [[#CAMF_99|CAMF]]
+|[[#Vandetanib_monotherapy_2|Vandetanib]]
-| style="background-color:#ffffbf" |Did not meet endpoint of OS
+| style="background-color:#d73027" |Inferior PFS
 |-
-|[https://doi.org/10.1200/JCO.1986.4.4.502 Miller et al. 1986 (SWOG S8012)]
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164813/ Elisei et al. 2013 (EXAM)]
-|1980-1983
+|2008-2011
 | style="background-color:#1a9851" |Phase 3 (C)
-|1. [[#FOMi_88|FOMi]]<br>2. [[#FOMi.2FCAP_88|FOMi/CAP]]
+|[[#Cabozantinib_monotherapy|Cabozantinib]]
-| style="background-color:#fc8d59" |Seems to have inferior OS
+| style="background-color:#d73027" |Inferior PFS
 |-
 |}
-<div class="toccolours" style="background-color:#b3e2cd">
+''No active antineoplastic treatment. Included for reference purposes only.''
-====Chemotherapy====
-*[[Cyclophosphamide (Cytoxan)]] 400 mg/m<sup>2</sup> IV once on day 1
-*[[Doxorubicin (Adriamycin)]] 40 mg/m<sup>2</sup> IV once on day 1
-*[[Cisplatin (Platinol)]] 40 mg/m<sup>2</sup> IV once on day 1
-'''21-day cycles'''
 </div></div>
 ===References===
-# Robert F, Omura GA, Birch R, Krauss S, Oldham R; SECG. Randomized phase III comparison of three doxorubicin-based chemotherapy regimens in advanced non-small cell lung cancer: a Southeastern Cancer Study Group trial. J Clin Oncol. 1984 May;2(5):391-5. [https://doi.org/10.1200/jco.1984.2.5.391 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/6374050/ PubMed]
+# '''ZETA:''' Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012 Jan 10;30(2):134-41. Epub 2011 Oct 24. [https://doi.org/10.1200/jco.2011.35.5040 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3675689/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/22025146 PubMed] NCT00410761
-# '''SWOG S8012:''' Miller TP, Chen TT, Coltman CA Jr, O'Bryan RM, Vance RB, Weiss GB, Fletcher WS, Stephens RL, Livingston RB. Effect of alternating combination chemotherapy on survival of ambulatory patients with metastatic large-cell and adenocarcinoma of the lung: a Southwest Oncology Group Study. J Clin Oncol. 1986 Apr;4(4):502-8. [https://doi.org/10.1200/JCO.1986.4.4.502 link to original article] [https://pubmed.ncbi.nlm.nih.gov/3007683 PubMed]
+# '''EXAM:''' Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013 Oct 10;31(29):3639-46. Epub 2013 Sep 3. Erratum in: J Clin Oncol. 2014 Jun 10;32(17):1864. [https://doi.org/10.1200/jco.2012.48.4659 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164813/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/24002501 PubMed] NCT00704730
-==Carboplatin & Cisplatin {{#subobject:a0e2a9|Regimen=1}}==
+==Sorafenib monotherapy {{#subobject:7e7480|Regimen=1}}==
-CC: '''<u>C</u>'''isplatin & '''<u>C</u>'''arboplatin
 <div class="toccolours" style="background-color:#eeeeee">
-===Regimen {{#subobject:e1bc46|Variant=1}}===
+===Regimen {{#subobject:1e2f21|Variant=1}}===
-{| class="wikitable sortable" style="width: 100%; text-align:center;"
+{| class="wikitable sortable" style="width: 60%; text-align:center;"
-!style="width: 20%"|Study
+!style="width: 33%"|Study
-!style="width: 20%"|Years of enrollment
+!style="width: 33%"|Years of enrollment
-!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 20%"|Comparator
-!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 |-
-|[https://doi.org/10.1200/JCO.1998.16.4.1388 Sculier et al. 1998]
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2881718/ Lam et al. 2010 (OSU 06054)]
-|1990-1995
+|2006-2008
-|style="background-color:#1a9851"|Phase 3 (C)
+| style="background-color:#91cf61" |Phase 2
-|[[#CCI|CCI]]
-| style="background-color:#d73027" |Inferior ORR
 |-
 |}
-''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.''
 <div class="toccolours" style="background-color:#b3e2cd">
-====Chemotherapy====
+====Targeted therapy====
-*[[Carboplatin (Paraplatin)]] 200 mg/m<sup>2</sup> IV once on day 1
+*[[Sorafenib (Nexavar)]] 400 mg PO twice per day
-*[[Cisplatin (Platinol)]] 30 mg/m<sup>2</sup> IV once per day on days 2 & 3
+'''Continued indefinitely'''
 </div></div>
 ===References===
-# Sculier JP, Paesmans M, Thiriaux J, Lecomte J, Bureau G, Giner V, Efremidis A, Lafitte JJ, Berchier MC, Alexopoulos CG, Zacharias C, Mommen P, Ninane V, Klastersky J; European Lung Cancer Working Party. Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. J Clin Oncol. 1998 Apr;16(4):1388-96. [https://doi.org/10.1200/JCO.1998.16.4.1388 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/9552042 PubMed]
+# '''OSU 06054:''' Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely PE Jr, Vasko VV, Saji M, Snyder PJ, Wei L, Arbogast D, Collamore M, Wright JJ, Moley JF, Villalona-Calero MA, Shah MH. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol. 2010 May 10;28(14):2323-30. Epub 2010 Apr 5. [https://doi.org/10.1200/jco.2009.25.0068 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2881718/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/20368568 PubMed] NCT00390325
-==CCI {{#subobject:a0532c|Regimen=1}}==
+==Sunitinib monotherapy {{#subobject:59fa83|Regimen=1}}==
-CCI: '''<u>C</u>'''isplatin, '''<u>C</u>'''arboplatin, '''<u>I</u>'''fosfamide
 <div class="toccolours" style="background-color:#eeeeee">
-===Regimen {{#subobject:ebjb16|Variant=1}}===
+===Regimen {{#subobject:7e9b73|Variant=1}}===
-{| class="wikitable sortable" style="width: 100%; text-align:center;"
+{| class="wikitable sortable" style="width: 60%; text-align:center;"
-!style="width: 20%"|Study
+!style="width: 33%"|Study
-!style="width: 20%"|Years of enrollment
+!style="width: 33%"|Years of enrollment
-!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 20%"|Comparator
-!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 |-
-|[https://doi.org/10.1200/JCO.1998.16.4.1388 Sculier et al. 1998]
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3063514/ Carr et al. 2010]
-|1990-1995
+|2007-2009
-|style="background-color:#1a9851"|Phase 3 (E-esc)
+| style="background-color:#91cf61" |Phase 2
-|[[#Carboplatin_.26_Cisplatin|CC]]
-| style="background-color:#1a9850" |Superior ORR
-|-
-|[https://doi.org/10.1093/annonc/mdf154 Sculier et al. 2002]
-|1998-2000
-|style="background-color:#1a9851"|Phase 3 (C)
-|1. [[Stub#CCG|CCG]]<br>2. [[#Ifosfamide_.26_Gemcitabine|IG]]
-| style="background-color:#ffffbf" |Seems not superior
 |-
 |}
 <div class="toccolours" style="background-color:#b3e2cd">
-====Chemotherapy====
+====Targeted therapy====
-*[[Carboplatin (Paraplatin)]]
+*[[Sunitinib (Sutent)]] 37.5 mg PO once per day
-*[[Cisplatin (Platinol)]]
+'''Continued indefinitely'''
-*[[Ifosfamide (Ifex)]]
-</div></div>
-===References===
-# Sculier JP, Paesmans M, Thiriaux J, Lecomte J, Bureau G, Giner V, Efremidis A, Lafitte JJ, Berchier MC, Alexopoulos CG, Zacharias C, Mommen P, Ninane V, Klastersky J; European Lung Cancer Working Party. Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. J Clin Oncol. 1998 Apr;16(4):1388-96. [https://doi.org/10.1200/JCO.1998.16.4.1388 link to original article] [https://pubmed.ncbi.nlm.nih.gov/9552042 PubMed]
-# Sculier JP, Lafitte JJ, Lecomte J, Berghmans T, Thiriaux J, Florin MC, Efremidis A, Alexopoulos CG, Recloux P, Ninane V, Mommen P, Paesmans M, Klastersky J; European Lung Cancer Working Party. A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer. Ann Oncol. 2002 Jun;13(6):874-82. [https://doi.org/10.1093/annonc/mdf154 link to original article] [https://pubmed.ncbi.nlm.nih.gov/12123332 PubMed]
-==Cisplatin monotherapy {{#subobject:a0eb49|Regimen=1}}==
-<div class="toccolours" style="background-color:#eeeeee">
-===Regimen {{#subobject:e32b46|Variant=1}}===
-{| class="wikitable sortable" style="width: 100%; text-align:center;"
-!style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
-!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 20%"|Comparator
-!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
-|-
-|[https://doi.org/10.1200/JCO.1993.11.5.873 Gandara et al. 1993]
-|1988-1990
-|style="background-color:#1a9851"|Phase 3 (C)
-|1. [[#Cisplatin_monotherapy_99|HDCP]]<br>2. [[#Cisplatin_.26_Mitomycin_99|HDCP-M]]
-| style="background-color:#ffffbf" |Seems not superior
-|-
-|[https://doi.org/10.1200/JCO.2000.18.6.1351 von Pawel et al. 2000 (CATAPULT I)]
-|NR
-|style="background-color:#1a9851"|Phase 3 (C)
-|[[#Cisplatin_.26_Tirapazamine_77|Cisplatin & Tirapazamine]]
-| style="background-color:#d73027" |Inferior OS
-|-
-|[https://doi.org/10.1200/JCO.2000.18.19.3390 Gatzemeier et al. 2000]
-|1995-1996
-|style="background-color:#1a9851"|Phase 3 (C)
-|[[Non-small_cell_lung_cancer#Cisplatin_.26_Paclitaxel|Cisplatin & Paclitaxel]]
-| style="background-color:#fc8d59" |Seems to have inferior TTP
-|-
-|}
-''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.''
-<div class="toccolours" style="background-color:#b3e2cd">
-====Chemotherapy====
-*[[Cisplatin (Platinol)]]
-</div></div>
-===References===
-# Gandara DR, Crowley J, Livingston RB, Perez EA, Taylor CW, Weiss G, Neefe JR, Hutchins LF, Roach RW, Grunberg SM, Braun TJ, Natale RB, Balcerzak SP; [[Study_Groups#SWOG|SWOG]]. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol. 1993 May;11(5):873-8. [https://doi.org/10.1200/JCO.1993.11.5.873 link to original article] [https://pubmed.ncbi.nlm.nih.gov/8387576 PubMed]
-# '''CATAPULT I:''' von Pawel J, von Roemeling R, Gatzemeier U, Boyer M, Elisson LO, Clark P, Talbot D, Rey A, Butler TW, Hirsh V, Olver I, Bergman B, Ayoub J, Richardson G, Dunlop D, Arcenas A, Vescio R, Viallet J, Treat J. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group: cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors. J Clin Oncol. 2000 Mar;18(6):1351-9. [https://doi.org/10.1200/JCO.2000.18.6.1351 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/10715308 PubMed]
-# Gatzemeier U, von Pawel J, Gottfried M, ten Velde GP, Mattson K, de Marinis F, Harper P, Salvati F, Robinet G, Lucenti A, Bogaerts J, Gallant G. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2000 Oct 1;18(19):3390-9. [https://doi.org/10.1200/JCO.2000.18.19.3390 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/11013280 PubMed]
-==Cisplatin & Pemetrexed {{#subobject:af12b4|Regimen=1}}==
-Pem-Cis: '''<u>Pem</u>'''etrexed & '''<u>Cis</u>'''platin
-<br>Cis-Pem: '''<u>Cis</u>'''platin & '''<u>Pem</u>'''etrexed
-<div class="toccolours" style="background-color:#eeeeee">
-===Regimen {{#subobject:8fdaa3|Variant=1}}===
-{| class="wikitable sortable" style="width: 100%; text-align:center;"
-!style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
-!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 20%"|Comparator
-!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
-|-
-|[https://doi.org/10.1200/jco.2007.15.0375 Scagliotti et al. 2008 (JMDB)]
-|2004-2005
-|style="background-color:#1a9851"|Phase 3 (E-RT-switch-ic)
-|[[Non-small_cell_lung_cancer#Cisplatin_.26_Gemcitabine_.28GC.29_3|Cisplatin & Gemcitabine]]
-|style="background-color:#eeee01"|Seems to have non-inferior OS
-|-
-|}
-''Note: although this regimen is still current for nonsquamous NSCLC, the JMDB trial was unselected by histology.''
-<div class="toccolours" style="background-color:#b3e2cd">
-====Chemotherapy====
-*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1, '''given second'''
-*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV over 10 minutes once on day 1, '''given first'''
-====Supportive therapy====
-*[[Cyanocobalamin (Vitamin B12)]] 1000 mcg IM every 9 weeks, first dose prior to [[Pemetrexed (Alimta)]]
-*Folic acid 1 mg PO once per day
-*In Sequist et al. 2013: Patients "received folic acid, vitamin B12, and dexamethasone, as per package recommendations for [[Pemetrexed (Alimta)]]."
-'''21-day cycle for 4 to 6 cycles'''
 </div></div>
 ===References===
-# '''JMDB:''' Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008 Jul 20;26(21):3543-51. Epub 2008 May 27. [https://doi.org/10.1200/jco.2007.15.0375 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/18506025 PubMed]
+# Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010 Nov 1;16(21):5260-8. Epub 2010 Sep 16. [https://doi.org/10.1158/1078-0432.CCR-10-0994 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3063514/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/20847059 PubMed]
-==Cisplatin & Vinblastine {{#subobject:2fe6d3|Regimen=1}}==
+==Vandetanib monotherapy {{#subobject:a85524|Regimen=1}}==
-VP: '''<u>V</u>'''inblastine & '''<u>P</u>'''latinol (Cisplatin)
 <div class="toccolours" style="background-color:#eeeeee">
-===Regimen {{#subobject:c5e07c|Variant=1}}===
+===Regimen variant #1, 100 mg/day {{#subobject:148745|Variant=1}}===
-{| class="wikitable sortable" style="width: 100%; text-align:center;"
+{| class="wikitable sortable" style="width: 60%; text-align:center;"
-!style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
-!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 20%"|Comparator
-!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
-|-
-|[https://doi.org/10.1200/JCO.1994.12.6.1113 Kosty et al. 1994 (CALGB 8931)]
-|1989-1991
-|style="background-color:#1a9851"|Phase 3 (C)
-|[[#Cisplatin.2C_Hydrazine.2C_Vinblastine_77|VP & Hydrazine]]
-|style="background-color:#ffffbf"|Seems not superior
-|-
-|}
-<div class="toccolours" style="background-color:#b3e2cd">
-====Chemotherapy====
-*[[Cisplatin (Platinol)]]
-*[[Vinblastine (Velban)]]
-</div></div>
-===References===
-# '''CALGB 8931:''' Kosty MP, Fleishman SB, Herndon JE 2nd, Coughlin K, Kornblith AB, Scalzo A, Morris JC, Mortimer J, Green MR; [[Study_Groups#CALGB|CALGB]]. Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B. J Clin Oncol. 1994 Jun;12(6):1113-20. [https://doi.org/10.1200/JCO.1994.12.6.1113 link to original article] [https://pubmed.ncbi.nlm.nih.gov/8201372 PubMed]
-==Cisplatin & Vindesine {{#subobject:80fe2|Regimen=1}}==
-VP: '''<u>V</u>'''indesine & '''<u>P</u>'''latinol (Cisplatin)
-<br>VdsC: '''<u>V</u>'''in'''<u>d</u>'''e'''<u>s</u>'''ine & '''<u>C</u>'''isplatin
-<div class="toccolours" style="background-color:#eeeeee">
-===Regimen {{#subobject:2d16cd|Variant=1}}===
-{| class="wikitable sortable" style="width: 100%; text-align:center;"
-!style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
-!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 20%"|Comparator
-!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
-|-
-|[https://doi.org/10.1200/JCO.1986.4.1.14 Ruckdeschel et al. 1986 (ECOG E1581)]
-|1981-1983
-|style="background-color:#1a9851"|Phase 3 (E-de-esc)
-|1. [[Non-small_cell_lung_cancer_-_historical#CAMP|CAMP]]<br>2. [[Non-small_cell_lung_cancer#Cisplatin_.26_Etoposide_.28EP.29|EC]]<br> 3. [[#MVP_.28Vinblastine.29|MVP]]
-|style="background-color:#ffffbf"|Seems not superior
-|-
-|[https://doi.org/10.1200/JCO.1988.6.4.633 Rapp et al. 1988]
-|1983-1986
-|style="background-color:#1a9851"|Phase 3 (E-esc)
-|[[#Best_supportive_care|Best supportive care]]
-| style="background-color:#1a9850" |Superior OS
-|-
-|[https://doi.org/10.1111/j.1440-1843.1996.tb00010.x Masutani et al. 1999]
-|1987-1992
-|style="background-color:#1a9851"|Phase 3 (C)
-|1. [[Stub#PVI|PVI]]<br>2. [[#MVP_.28Vindesine.29|PVM]]
-|style="background-color:#ffffbf"|Seems not superior
-|-
-|[https://doi.org/10.1016/s0169-5002(02)00008-9 Kodani et al. 2002]
-|1987-1992
-|style="background-color:#1a9851"|Phase 3 (C)
-|[[Stub#PVI|PVI]]
-|style="background-color:#ffffbf"|Seems not superior
-|-
-|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747545/ Negoro et al. 2003]
-|1995-1998
-|style="background-color:#1a9851"|Phase 3 (C)
-|[[Non-small_cell_lung_cancer#Cisplatin_.26_Irinotecan_.28IC.29|Cisplatin & Irinotecan]]
-|style="background-color:#ffffbf"|Seems not superior
-|-
-|[https://doi.org/10.1023/a:1012208711013 Vansteenkiste et al. 2001]
-|1996-1999
-|style="background-color:#1a9851"|Phase 3 (C)
-|[[#Gemcitabine_monotherapy|Gemcitabine]]
-| style="background-color:#fc8d59" |Seems to have inferior clinical benefit
-|-
-|[https://doi.org/10.1200/JCO.2004.06.114 Kubota et al. 2004]
-|1998-2000
-|style="background-color:#1a9851"|Phase 3 (E-switch-ic)
-|[[Non-small_cell_lung_cancer#Cisplatin_.26_Docetaxel_.28DC.29_3|Cisplatin & Docetaxel]]
-| style="background-color:#fc8d59" |Seems to have inferior OS
-|-
-|}
-<div class="toccolours" style="background-color:#b3e2cd">
-====Chemotherapy====
-*[[Cisplatin (Platinol)]]
-*[[Vindesine (Eldisine)]]
-</div></div>
-===References===
-# '''ECOG E1581:''' Ruckdeschel JC, Finkelstein DM, Ettinger DS, Creech RH, Mason BA, Joss RA, Vogl S. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol. 1986 Jan;4(1):14-22. [https://doi.org/10.1200/JCO.1986.4.1.14 link to original article] [https://pubmed.ncbi.nlm.nih.gov/3510278 PubMed]
-# Rapp E, Pater JL, Willan A, Cormier Y, Murray N, Evans WK, Hodson DI, Clark DA, Feld R, Arnold AM, Ayoub JI, Wilson KS, Latreille J, Wierzbicki RF, Hill DP. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial. J Clin Oncol. 1988 Apr;6(4):633-41. [https://doi.org/10.1200/JCO.1988.6.4.633 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2833577 PubMed]
-# Masutani M, Akusawa H, Kadota A, Ohchi Y, Takahashi N, Tanigawa S, Koya Y, Horie T. A phase III randomized trial of cisplatin plus vindesine versus cisplatin plus vindesine plus mitomycin C versus cisplatin plus vindesine plus ifosfamide for advanced non-small-cell lung cancer. Respirology. 1996 Mar;1(1):49-54. [https://doi.org/10.1111/j.1440-1843.1996.tb00010.x link to original article] [https://pubmed.ncbi.nlm.nih.gov/9432405 PubMed]
-# Vansteenkiste JF, Vandebroek JE, Nackaerts KL, Weynants P, Valcke YJ, Verresen DA, Devogelaere RC, Marien SA, Humblet YP, Dams NL; Leuven Lung Cancer Group. Clinical-benefit response in advanced non-small-cell lung cancer: a multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine. Ann Oncol. 2001 Sep;12(9):1221-30. [https://doi.org/10.1023/a:1012208711013 link to original article] [https://pubmed.ncbi.nlm.nih.gov/11697832 PubMed]
-# Kodani T, Ueoka H, Kiura K, Tabata M, Takigawa N, Segawa Y, Moritaka T, Hiraki S, Harada M, Tanimoto M. A phase III randomized trial comparing vindesine and cisplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer: long-term follow-up results and analysis of prognostic factors. Lung Cancer. 2002 Jun;36(3):313-9. [https://doi.org/10.1016/s0169-5002(02)00008-9 link to original article] [https://pubmed.ncbi.nlm.nih.gov/12009244 PubMed]
-# Negoro S, Masuda N, Takada Y, Sugiura T, Kudoh S, Katakami N, Ariyoshi Y, Ohashi Y, Niitani H, Fukuoka M; CPT-11 Lung Cancer Study Group West. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer. 2003 Feb 10;88(3):335-41. [https://doi.org/10.1038/sj.bjc.6600725 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747545/ link to PMC article] '''contains dosing details in manuscript'''  [https://pubmed.ncbi.nlm.nih.gov/12569373 PubMed]
-# Kubota K, Watanabe K, Kunitoh H, Noda K, Ichinose Y, Katakami N, Sugiura T, Kawahara M, Yokoyama A, Yokota S, Yoneda S, Matsui K, Kudo S, Shibuya M, Isobe T, Segawa Y, Nishiwaki Y, Ohashi Y, Niitani H; Japanese Taxotere Lung Cancer Study Group. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol. 2004 Jan 15;22(2):254-61. [https://doi.org/10.1200/JCO.2004.06.114 link to original article] [https://pubmed.ncbi.nlm.nih.gov/14722033 PubMed]
-==Docetaxel monotherapy {{#subobject:ec36b5|Regimen=1}}==
-<div class="toccolours" style="background-color:#eeeeee">
-===Regimen {{#subobject:dd8369|Variant=1}}===
-{| class="wikitable sortable" style="width: 100%; text-align:center;"
-!style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
-!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 20%"|Comparator
-!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
-|-
-|[https://doi.org/10.1016/s0169-5002(00)00094-5 Roszkowski et al. 2000]
-|1995-NR
-|style="background-color:#1a9851"|Phase 3 (E-esc)
-|[[#Best_supportive_care|Best supportive care]]
-| style="background-color:#91cf60" |Seems to have superior OS
-|-
-|[https://doi.org/10.1016/j.lungcan.2007.07.021 Georgoulias et al. 2007]
-|2002-2004
-|style="background-color:#1a9851"|Phase 3 (C)
-|[[#Docetaxel_.26_Gemcitabine|DG]]
-| style="background-color:#fc8d59" |Seems to have inferior OS
-|-
-|}
-<div class="toccolours" style="background-color:#b3e2cd">
-====Chemotherapy====
-*[[Docetaxel (Taxotere)]]
-</div></div>
-===References===
-# Roszkowski K, Pluzanska A, Krzakowski M, Smith AP, Saigi E, Aasebo U, Parisi A, Pham Tran N, Olivares R, Berille J. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer. 2000 Mar;27(3):145-57. [https://doi.org/10.1016/s0169-5002(00)00094-5 link to original article] [https://pubmed.ncbi.nlm.nih.gov/10699688 PubMed]
-# Georgoulias V, Androulakis N, Kotsakis A, Hatzidaki D, Syrigos K, Polyzos A, Agelidou A, Varthalitis I, Ziras N, Agelidou M, Chandrinos V, Boukovinas I, Geroyianni A, Vamvakas L, Mavroudis D. Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial. Lung Cancer. 2008 Jan;59(1):57-63. Epub 2007 Aug 31. [https://doi.org/10.1016/j.lungcan.2007.07.021 link to original article] [https://pubmed.ncbi.nlm.nih.gov/17765354 PubMed]
-==Docetaxel & Gemcitabine {{#subobject:80fe2|Regimen=1}}==
-DG: '''<u>D</u>'''ocetaxel & '''<u>G</u>'''emcitabine
-<div class="toccolours" style="background-color:#eeeeee">
-===Regimen {{#subobject:2d16cd|Variant=1}}===
-{| class="wikitable sortable" style="width: 100%; text-align:center;"
-!style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
-!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 20%"|Comparator
-!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
-|-
-|[https://doi.org/10.1016/j.lungcan.2007.07.021 Georgoulias et al. 2007]
-|2002-2004
-|style="background-color:#1a9851"|Phase 3 (E-esc)
-|[[#Docetaxel_monotherapy|Docetaxel]]
-| style="background-color:#91cf60" |Seems to have superior OS
-|-
-|}
-''Note: while this is a superior arm of a phase III RCT, the comparator (single-agent docetaxel) is not usually used in the first-line treatment and this regimen is not currently recommended by ESMO guidelines.''
-<div class="toccolours" style="background-color:#b3e2cd">
-====Chemotherapy====
-*[[Docetaxel (Taxotere)]]
-*[[Gemcitabine (Gemzar)]]
-</div></div>
-===References===
-# Georgoulias V, Androulakis N, Kotsakis A, Hatzidaki D, Syrigos K, Polyzos A, Agelidou A, Varthalitis I, Ziras N, Agelidou M, Chandrinos V, Boukovinas I, Geroyianni A, Vamvakas L, Mavroudis D. Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial. Lung Cancer. 2008 Jan;59(1):57-63. Epub 2007 Aug 31. [https://doi.org/10.1016/j.lungcan.2007.07.021 link to original article] [https://pubmed.ncbi.nlm.nih.gov/17765354 PubMed]
-==Ifosfamide & Gemcitabine {{#subobject:80fe2|Regimen=1}}==
-IG: '''<u>I</u>'''fosfamide & '''<u>G</u>'''emcitabine
-<div class="toccolours" style="background-color:#eeeeee">
-===Regimen {{#subobject:2d16cd|Variant=1}}===
-{| class="wikitable sortable" style="width: 100%; text-align:center;"
-!style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
-!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 20%"|Comparator
-!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
-|-
-|[https://doi.org/10.1093/annonc/mdf154 Sculier et al. 2002]
-|1998-2000
-|style="background-color:#1a9851"|Phase 3 (E-esc)
-|1. [[#CCI|CCI]]<br>2. [[Stub#CCG|CCG]]
-| style="background-color:#ffffbf" |Seems not superior
-|-
-|[http://ar.iiarjournals.org/content/33/12/5477.long Berghmans et al. 2013 (ELCWP-01041)]
-|2003-2009
-|style="background-color:#1a9851"|Phase 3 (C)
-|1. [[#GIP|GIP]]<br>2. [[Non-small_cell_lung_cancer#Cisplatin_.26_Docetaxel_.28DC.29_3|DP]]
-| style="background-color:#ffffbf" |Seems not superior
-|-
-|}
-''Note: this is an experimental arm that did not meet its primary endpoint; included here because it was eventually used to establish this regimen as a standard comparator.''
-<div class="toccolours" style="background-color:#b3e2cd">
-====Chemotherapy====
-*[[Ifosfamide (Ifex)]]
-*[[Gemcitabine (Gemzar)]]
-</div></div>
-===References===
-# Sculier JP, Lafitte JJ, Lecomte J, Berghmans T, Thiriaux J, Florin MC, Efremidis A, Alexopoulos CG, Recloux P, Ninane V, Mommen P, Paesmans M, Klastersky J; European Lung Cancer Working Party. A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer. Ann Oncol. 2002 Jun;13(6):874-82. [https://doi.org/10.1093/annonc/mdf154 link to original article] [https://pubmed.ncbi.nlm.nih.gov/12123332 PubMed]
-# '''ELCWP-01041:''' Berghmans T, Lafitte JJ, Scherpereel A, Paesmans M, Lecomte J, Marco VG, Meert AP, Leclercq N, Sculier JP; European Lung Cancer Working Party. An ELCWP phase III trial comparing ifosfamide and cisplatin regimens in advanced NSCLC. Anticancer Res. 2013 Dec;33(12):5477-82. [http://ar.iiarjournals.org/content/33/12/5477.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/24324084 PubMed] NCT00622349
-==Gemcitabine monotherapy {{#subobject:826de2|Regimen=1}}==
-<div class="toccolours" style="background-color:#eeeeee">
-===Regimen {{#subobject:4b26cd|Variant=1}}===
-{| class="wikitable sortable" style="width: 100%; text-align:center;"
-!style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
-!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 20%"|Comparator
-!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
-|-
-|[https://doi.org/10.1023/a:1012208711013 Vansteenkiste et al. 2001]
-|1996-1999
-|style="background-color:#1a9851"|Phase 3 (E-de-esc)
-|[[#Cisplatin_.26_Vindesine|Cisplatin & Vindesine]]
-| style="background-color:#91cf60" |Seems to have superior clinical benefit
-|-
-|[https://doi.org/10.1200/jco.2005.01.2781 Sederholm et al. 2005]
-|1998-2001
-|style="background-color:#1a9851"|Phase 3 (C)
-|[[Non-small_cell_lung_cancer#Carboplatin_.26_Gemcitabine_.28GCb.29|Carboplatin & Gemcitabine]]
-| style="background-color:#fc8d59" |Seems to have inferior OS
-|-
-|}
-''Note: this regimen is considered current in elderly patients or those with poor PS; these trials were unselected by these parameters.''
-<div class="toccolours" style="background-color:#b3e2cd">
-====Chemotherapy====
-*[[Gemcitabine (Gemzar)]]
-</div></div>
-===References===
-# Vansteenkiste JF, Vandebroek JE, Nackaerts KL, Weynants P, Valcke YJ, Verresen DA, Devogelaere RC, Marien SA, Humblet YP, Dams NL; Leuven Lung Cancer Group. Clinical-benefit response in advanced non-small-cell lung cancer: a multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine. Ann Oncol. 2001 Sep;12(9):1221-30. [https://doi.org/10.1023/a:1012208711013 link to original article] [https://pubmed.ncbi.nlm.nih.gov/11697832 PubMed]
-# Sederholm C, Hillerdal G, Lamberg K, Kölbeck K, Dufmats M, Westberg R, Gawande SR. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: Swedish Lung Cancer Study Group. J Clin Oncol. 2005 Nov 20;23(33):8380-8. [https://doi.org/10.1200/jco.2005.01.2781 link to original article] [https://pubmed.ncbi.nlm.nih.gov/16293868 PubMed]
-==GIP {{#subobject:2c098d|Regimen=1}}==
-GIP: '''<u>G</u>'''emcitabine, '''<u>I</u>'''fosfamide, '''<u>P</u>'''latinol (Cisplatin)
-<div class="toccolours" style="background-color:#eeeeee">
-===Regimen {{#subobject:9a4cf6|Variant=1}}===
-{| class="wikitable" style="width: 60%; text-align:center;"
 !style="width: 33%"|Study
 !style="width: 33%"|Years of enrollment
 !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 |-
-|[https://doi.org/10.1093/annonc/mdm084 Sculier et al. 2007]
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2902067/ Robinson et al. 2010 (D4200C00068)]
-|2000-2004
+|2006-2007
-| style="background-color:#91cf61" |Non-randomized portion of phase 3 RCT
+| style="background-color:#ffffbe" |Phase 2, <20 patients
 |-
 |}
 <div class="toccolours" style="background-color:#b3e2cd">
-====Chemotherapy====
+====Targeted therapy====
-*[[Gemcitabine (Gemzar)]]
+*[[Vandetanib (Caprelsa)]] 100 mg PO once per day
-*[[Ifosfamide (Ifex)]]
+'''Continued indefinitely'''
-*[[Cisplatin (Platinol)]]
+</div>
-</div></div>
+<div class="toccolours" style="background-color:#cbd5e7">
-===References===
+====Subsequent treatment====
-# Sculier JP, Lafitte JJ, Lecomte J, Alexopoulos CG, Van Cutsem O, Giner V, Efremidis A, Berchier MC, Collon T, Meert AP, Scherpereel A, Ninane V, Paesmans M, Berghmans T; European Lung Cancer Working Party. A phase III randomised trial comparing sequential chemotherapy using cisplatin-based regimen and paclitaxel to cisplatin-based chemotherapy alone in advanced non-small-cell lung cancer. Ann Oncol. 2007 Jun;18(6):1037-42. Epub 2007 Apr 2. [https://doi.org/10.1093/annonc/mdm084 link to original article] [https://pubmed.ncbi.nlm.nih.gov/17404152 PubMed]
+*At progression, eligible patients could increase the dose to 300 mg PO once per day; see paper for details
-==MACC {{#subobject:3f2f0c|Regimen=1}}==
+</div></div><br>
-MACC: '''<u>M</u>'''ethotrexate, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>C</u>'''CNU (Lomustine)
 <div class="toccolours" style="background-color:#eeeeee">
-===Regimen {{#subobject:cec9d6|Variant=1}}===
+===Regimen variant #2, 300 mg/day {{#subobject:e75f4f|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 !style="width: 20%"|Study
@@ Line 642: / Line 156: @@
 !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 |-
-|[https://jamanetwork.com/journals/jama/article-abstract/353407 Chahinian et al. 1977]
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834392/ Wells et al. 2010]
-|NR
+|2004-2006
-| style="background-color:#91cf61" |Non-randomized
+| style="background-color:#91cf61" |Phase 2
 | style="background-color:#d3d3d3" |
 | style="background-color:#d3d3d3" |
 |-
-|[https://doi.org/10.1002/1097-0142(19820901)50:5%3C845::AID-CNCR2820500507%3E3.0.CO;2-S Cormier et al. 1982]
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3675689/ Wells et al. 2011 (ZETA)]
-|NR
+|2006-2007
-|style="background-color:#1a9851"|Phase 3 (E-esc)
+| style="background-color:#1a9851" |Phase 3 (E-RT-esc)
-|[[#Placebo|Placebo]]
+|[[#Placebo_2|Placebo]]
-|style="background-color:#1a9850"|Superior OS
+| style="background-color:#1a9850" |Superior PFS<br>Median PFS: NYR vs 19.3 mo<br>(HR 0.46, 95% CI 0.31-0.69)
 |-
 |}
 <div class="toccolours" style="background-color:#b3e2cd">
-====Chemotherapy====
+====Targeted therapy====
-*[[Methotrexate (MTX)]]
+*[[Vandetanib (Caprelsa)]] 300 mg PO once per day
-*[[Doxorubicin (Adriamycin)]]
+'''Continued indefinitely'''
-*[[Cyclophosphamide (Cytoxan)]]
-*[[Lomustine (CCNU)]]
 </div></div>
 ===References===
-# Chahinian PA, Arnold DJ, Cohen JM, Purpora DP, Jaffrey IS, Teirstein AS, Kirschner PA, Holland JF. Chemotherapy for bronchogenic carcinoma: methotrexate, doxorubicin, cyclophosphamide, and lomustine. JAMA. 1977 May 30;237(22):2392-6. [https://jamanetwork.com/journals/jama/article-abstract/353407 link to original article] [https://pubmed.ncbi.nlm.nih.gov/576939 PubMed]
+# Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J, Schlumberger M. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2010 Feb 10;28(5):767-72. Epub 2010 Jan 11. [https://doi.org/10.1200/jco.2009.23.6604 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834392/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/20065189 PubMed]
-# Cormier Y, Bergeron D, La Forge J, Lavandier M, Fournier M, Chenard J, Desmeules M. Benefits of polychemotherapy in advanced non-small-cell bronchogenic carcinoma. Cancer. 1982 Sep 1;50(5):845-9. [https://doi.org/10.1002/1097-0142(19820901)50:5%3C845::AID-CNCR2820500507%3E3.0.CO;2-S link to original article] [https://pubmed.ncbi.nlm.nih.gov/7093924 PubMed]
+# '''D4200C00068:''' Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 2010 Jun;95(6):2664-71. Epub 2010 Apr 6. [https://doi.org/10.1210/jc.2009-2461 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2902067/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/20371662 PubMed] content property of [http://hemonc.org HemOnc.org] NCT00358956
-==MIC {{#subobject:d1b4dd|Regimen=1}}==
+# '''ZETA:''' Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012 Jan 10;30(2):134-41. Epub 2011 Oct 24. [https://doi.org/10.1200/jco.2011.35.5040 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3675689/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/22025146 PubMed] NCT00410761
-MIC: '''<u>M</u>'''itomycin, '''<u>I</u>'''fosfamide, '''<u>C</u>'''isplatin
+=Advanced or metastatic disease=
-<br>MIP: '''<u>M</u>'''itomycin, '''<u>I</u>'''fosfamide, '''<u>P</u>'''latinol (Cisplatin)
+==Axitinib monotherapy {{#subobject:73fcb6|Regimen=1}}==
 <div class="toccolours" style="background-color:#eeeeee">
-===Regimen {{#subobject:99a9f2|Variant=1}}===
+===Regimen {{#subobject:aff447|Variant=1}}===
-{| class="wikitable sortable" style="width: 100%; text-align:center;"
+{| class="wikitable sortable" style="width: 60%; text-align:center;"
-!style="width: 20%"|Study
+!style="width: 33%"|Study
-!style="width: 20%"|Years of enrollment
+!style="width: 33%"|Years of enrollment
-!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 20%"|Comparator
-!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
-|-
-|[https://doi.org/10.1200/JCO.1999.17.10.3188 Cullen et al. 1999 (MIC2)]
-|1988-1996
-|style="background-color:#1a9851"|Phase 3 (E-esc)
-|[[#Best_supportive_care|Best supportive care]]
-|style="background-color:#91cf60"|Seems to have superior OS
-|-
-|[https://doi.org/10.1200/JCO.1999.17.11.3522 Crinò et al. 1999]
-|1995-1997
-|style="background-color:#1a9851"|Phase 3 (C)
-|[[Non-small_cell_lung_cancer#Cisplatin_.26_Gemcitabine_.28GC.29_3|Cisplatin & Gemcitabine]]
-| style="background-color:#fc8d59" |Seems to have inferior ORR
-|-
-|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363584/ Sculier et al. 2000]
-|1995-1998
-|style="background-color:#1a9851"|Phase 3 (C)
-|[[Stub#CarboMIP|CarboMIP]]
-|style="background-color:#ffffbf"|Seems not superior
-|-
-|[https://doi.org/10.1002/cncr.11535 Danson et al. 2003]
-|1997-2001
-|style="background-color:#1a9851"|Phase 3 (C)
-|[[Non-small_cell_lung_cancer#Carboplatin_.26_Gemcitabine_.28GCb.29|GC]]
-|style="background-color:#ffffbf"|Seems not superior
-|-
-|[https://doi.org/10.1093/annonc/mdl078 Booton et al. 2006 (BTOG1)]
-|2001-2002
-|style="background-color:#1a9851"|Phase 3 (C)
-|[[Non-small_cell_lung_cancer#Carboplatin_.26_Docetaxel|DCb]]
-|style="background-color:#ffffbf"|Seems not superior
-|-
-|}
-<div class="toccolours" style="background-color:#b3e2cd">
-====Chemotherapy====
-*[[Mitomycin (Mutamycin)]]
-*[[Ifosfamide (Ifex)]]
-*[[Cisplatin (Platinol)]]
-</div></div>
-===References===
-# '''MIC2:''' Cullen MH, Billingham LJ, Woodroffe CM, Chetiyawardana AD, Gower NH, Joshi R, Ferry DR, Rudd RM, Spiro SG, Cook JE, Trask C, Bessell E, Connolly CK, Tobias J, Souhami RL. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol. 1999 Oct;17(10):3188-94. [https://doi.org/10.1200/JCO.1999.17.10.3188 link to original article] [https://pubmed.ncbi.nlm.nih.gov/10506617 PubMed]
-# Crinò L, Scagliotti GV, Ricci S, De Marinis F, Rinaldi M, Gridelli C, Ceribelli A, Bianco R, Marangolo M, Di Costanzo F, Sassi M, Barni S, Ravaioli A, Adamo V, Portalone L, Cruciani G, Masotti A, Ferrara G, Gozzelino F, Tonato M. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol. 1999 Nov;17(11):3522-30. [https://doi.org/10.1200/JCO.1999.17.11.3522 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/10550150 PubMed]
-# Sculier JP, Lafitte JJ, Paesmans M, Thiriaux J, Alexopoulos CG, Baumöhl J, Schmerber J, Koumakis G, Florin MC, Zacharias C, Berghmans T, Mommen P, Ninane V, Klastersky J. Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer. Br J Cancer. 2000 Nov;83(9):1128-35. [https://doi.org/10.1054/bjoc.2000.1413 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363584/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/11027424 PubMed]
-# Danson S, Middleton MR, O'Byrne KJ, Clemons M, Ranson M, Hassan J, Anderson H, Burt PA, Fairve-Finn C, Stout R, Dowd I, Ashcroft L, Beresford C, Thatcher N. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer. 2003 Aug 1;98(3):542-53. [https://doi.org/10.1002/cncr.11535 link to original article] [https://pubmed.ncbi.nlm.nih.gov/12879472 PubMed]
-# '''BTOG1:''' Booton R, Lorigan P, Anderson H, Baka S, Ashcroft L, Nicolson M, O'Brien M, Dunlop D, O'Byrne K, Laurence V, Snee M, Dark G, Thatcher N. A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). Ann Oncol. 2006 Jul;17(7):1111-9. Epub 2006 Apr 7. [https://doi.org/10.1093/annonc/mdl078 link to original article] [https://pubmed.ncbi.nlm.nih.gov/16603599 PubMed]
-==MVP (Vinblastine) {{#subobject:eb48eb|Regimen=1}}==
-MVP: '''<u>M</u>'''itomycin, '''<u>V</u>'''inblastine, '''<u>P</u>'''latinol (Cisplatin)
-<div class="toccolours" style="background-color:#eeeeee">
-===Regimen {{#subobject:883648|Variant=1}}===
-{| class="wikitable sortable" style="width: 100%; text-align:center;"
-!style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
-!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 20%"|Comparator
-!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
-|-
-|[https://doi.org/10.1200/JCO.1986.4.1.14 Ruckdeschel et al. 1986 (ECOG E1581)]
-|1981-1983
-|style="background-color:#1a9851"|Phase 3 (E-de-esc)
-|1. [[Non-small_cell_lung_cancer_-_historical#CAMP|CAMP]]<br>2. [[Non-small_cell_lung_cancer#Cisplatin_.26_Etoposide_.28EP.29|EC]]<br> 3. [[#Cisplatin_.26_Vindesine|VC]]
-|style="background-color:#ffffbf"|Seems not superior
-|-
-|[https://doi.org/10.1200/JCO.1989.7.11.1602 Bonomi et al. 1989 (ECOG E1583)]
-|1984-1985
-|style="background-color:#1a9851"|Phase 3 (C)
-|1. [[#Cisplatin_.26_Vinblastine_99|VP]]<br>2. [[#MVP.2FCAMP_99|MVP/CAMP]]<br> 3. [[#Carboplatin_monotherapy_99|Carboplatin]]<br> 4. [[#Iproplatin_monotherapy_77|Iproplatin]]
-|style="background-color:#ffffbf"|Seems not superior
-|-
-|[https://doi.org/10.1002/1097-0142(19921101)70:9%3C2281::AID-CNCR2820700912%3E3.0.CO;2-9 Veeder et al. 1992]
-|NR
-|style="background-color:#1a9851"|Phase 3 (C)
-|[[#Mitomycin_monotherapy_99|Mitomycin]]
-| style="background-color:#d9ef8b" |Might have superior OS
-|-
-|[https://doi.org/10.1200/JCO.2001.19.5.1336 Smith et al. 2001]
-|1995-1998
-|style="background-color:#1a9851"|Phase 3 (C)
-|[[#MVP_.28Vinblastine.29|MVP]] x 3
-|style="background-color:#ffffbf"|Seems not superior
-|-
-|[https://doi.org/10.1002/cncr.11535 Danson et al. 2003]
-|1997-2001
-|style="background-color:#1a9851"|Phase 3 (C)
-|[[Non-small_cell_lung_cancer#Carboplatin_.26_Gemcitabine_.28GCb.29|GC]]
-|style="background-color:#ffffbf"|Seems not superior
-|-
-|[https://doi.org/10.1093/annonc/mdl078 Booton et al. 2006 (BTOG1)]
-|2001-2002
-|style="background-color:#1a9851"|Phase 3 (C)
-|[[Non-small_cell_lung_cancer#Carboplatin_.26_Docetaxel|DCb]]
-|style="background-color:#ffffbf"|Seems not superior
-|-
-|}
-<div class="toccolours" style="background-color:#b3e2cd">
-====Chemotherapy====
-*[[Mitomycin (Mutamycin)]]
-*[[Vinblastine (Velban)]]
-*[[Cisplatin (Platinol)]]
-</div></div>
-===References===
-# '''ECOG E1581:''' Ruckdeschel JC, Finkelstein DM, Ettinger DS, Creech RH, Mason BA, Joss RA, Vogl S. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol. 1986 Jan;4(1):14-22. [https://doi.org/10.1200/JCO.1986.4.1.14 link to original article] [https://pubmed.ncbi.nlm.nih.gov/3510278 PubMed]
-# '''ECOG E1583:''' Bonomi PD, Finkelstein DM, Ruckdeschel JC, Blum RH, Green MD, Mason B, Hahn R, Tormey DC, Harris J, Comis R, Glick J. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol. 1989 Nov;7(11):1602-13. [https://doi.org/10.1200/JCO.1989.7.11.1602 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2553879 PubMed]
-# Veeder MH, Jett JR, Su JQ, Mailliard JA, Foley JF, Dalton RJ, Etzell PS, Marschke RF Jr, Kardinal CG, Maksymiuk AW, Ebbert LP, Tazelaar HD, Witrak GA. A phase III trial of mitomycin C alone versus mitomycin C, vinblastine, and cisplatin for metastatic squamous cell lung carcinoma. Cancer. 1992 Nov 1;70(9):2281-7. [https://doi.org/10.1002/1097-0142(19921101)70:9%3C2281::AID-CNCR2820700912%3E3.0.CO;2-9 link to original article] [https://pubmed.ncbi.nlm.nih.gov/1394057 PubMed]
-# Smith IE, O'Brien ME, Talbot DC, Nicolson MC, Mansi JL, Hickish TF, Norton A, Ashley S. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol. 2001 Mar 1;19(5):1336-43. [https://doi.org/10.1200/JCO.2001.19.5.1336 link to original article] [https://pubmed.ncbi.nlm.nih.gov/11230476 PubMed]
-# Danson S, Middleton MR, O'Byrne KJ, Clemons M, Ranson M, Hassan J, Anderson H, Burt PA, Fairve-Finn C, Stout R, Dowd I, Ashcroft L, Beresford C, Thatcher N. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer. 2003 Aug 1;98(3):542-53. [https://doi.org/10.1002/cncr.11535 link to original article] [https://pubmed.ncbi.nlm.nih.gov/12879472 PubMed]
-# '''BTOG1:''' Booton R, Lorigan P, Anderson H, Baka S, Ashcroft L, Nicolson M, O'Brien M, Dunlop D, O'Byrne K, Laurence V, Snee M, Dark G, Thatcher N. A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). Ann Oncol. 2006 Jul;17(7):1111-9. Epub 2006 Apr 7. [https://doi.org/10.1093/annonc/mdl078 link to original article] [https://pubmed.ncbi.nlm.nih.gov/16603599 PubMed]
-==MVP (Vindesine) {{#subobject:5258ea|Regimen=1}}==
-MVP: '''<u>M</u>'''itomycin, '''<u>V</u>'''indesine, '''<u>P</u>'''latinol (Cisplatin)
-<br>PVM: '''<u>P</u>'''latinol (Cisplatin), '''<u>V</u>'''indesine, '''<u>M</u>'''itomycin
-<div class="toccolours" style="background-color:#eeeeee">
-===Regimen {{#subobject:ffec94|Variant=1}}===
-{| class="wikitable sortable" style="width: 100%; text-align:center;"
-!style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
-!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 20%"|Comparator
-!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
-|-
-|[https://doi.org/10.1093/oxfordjournals.annonc.a058834 González Barón et al. 1994]
-|1989-1992
-|style="background-color:#1a9851"|Phase 3 (E-switch-ic)
-|[[#MIC_3|MIP]]
-| style="background-color:#ffffbf" |Seems not superior
-|-
-|[https://doi.org/10.1093/oxfordjournals.annonc.a010761 Gridelli et al. 1996]
-|1990-1994
-|style="background-color:#1a9851"|Phase 3 (C)
-|[[Stub#MEV|MEV]]
-| style="background-color:#ffffbf" |Seems not superior
-|-
-|[https://doi.org/10.1016/s0169-5002(01)00239-2 Jelić et al. 2001]
-|1990-1996
-|style="background-color:#1a9851"|Phase 3 (C)
-|[[Stub#MVC|MVC]]
-| style="background-color:#d73027" |Inferior OS
-|-
-|[https://doi.org/10.1016/s0959-8049(98)00231-7 Boni et al. 1998]
-|1992-1996
-|style="background-color:#1a9851"|Phase 3 (C)
-|[[#MVP_.28Vindesine.29|MVP]]; CI
-| style="background-color:#ffffbf" |Seems not superior
-|-
-|}
-<div class="toccolours" style="background-color:#b3e2cd">
-====Chemotherapy====
-*[[Mitomycin (Mutamycin)]]
-*[[Vindesine (Eldisine)]]
-*[[Cisplatin (Platinol)]]
-</div></div>
-===References===
-# González Barón M, Feliu J, Espinosa E, García Girón C, Blanco E, Garrido P, Colmenarejo A, Ordóñez A, Moyano A, de la Gándara I, Zamora P; ONCOPAZ Cooperative Group. Comparison of two chemotherapeutic regimens--mitomycin + vindesine + cisplatin (MVP) vs mitomycin + ifosfamide + cisplatin (MIP)--in advanced non-small-cell lung cancer. Ann Oncol. 1994 Apr;5(4):323-7. [https://doi.org/10.1093/oxfordjournals.annonc.a058834 link to original article] [https://pubmed.ncbi.nlm.nih.gov/8075028 PubMed]
-# Gridelli C, Perrone F, Palmeri S, D'Aprile M, Cognetti F, Rossi A, Gebbia V, Pepe R, Veltri E, Airoma G, Russo A, Incoronato P, Scinto AF, Palazzolo G, Natali M, Leonardi V, Gallo C, De Placido S, Bianco AR; GOSCI. Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phase III multicentre randomised trial. Ann Oncol. 1996 Oct;7(8):821-6. [https://doi.org/10.1093/oxfordjournals.annonc.a010761 link to original article] [https://pubmed.ncbi.nlm.nih.gov/8922196 PubMed]
-# Boni C, Savoldi L, Bisagni G, Ceci G, Crinò L, De Lisi V, Di Costanzo F, Lasagni L, Manenti AL, Moretti G, Rondini E, Sassi M, Zadro A; GOIRC. Bolus versus 5-day continuous infusion of cisplatin with mitomycin and vindesine in the treatment of advanced non-small cell lung cancer (NSCLC): a phase III prospective randomised trial of the Italian Oncology Group for Clinical Research (GOIRC). Eur J Cancer. 1998 Nov;34(12):1974-6. [https://doi.org/10.1016/s0959-8049(98)00231-7 link to original article] [https://pubmed.ncbi.nlm.nih.gov/10023325 PubMed]
-# Jelić S, Mitrović L, Radosavljević D, Elezar E, Babović N, Kovcin V, Tomasević Z, Kovacević S, Gavrilović D, Radulović S. Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study. Lung Cancer. 2001 Oct;34(1):1-13. [https://doi.org/10.1016/s0169-5002(01)00239-2 link to original article] [https://pubmed.ncbi.nlm.nih.gov/11557107 PubMed]
-==Paclitaxel monotherapy {{#subobject:a87044|Regimen=1}}==
-<div class="toccolours" style="background-color:#eeeeee">
-===Regimen variant #1, 100 mg/m<sup>2</sup>, 3 out of 4 weeks {{#subobject:866dac|Variant=1}}===
-{| class="wikitable sortable" style="width: 100%; text-align:center;"
-!style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
-!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 20%"|Comparator
-!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
-|-
-|rowspan=2|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409832/ Comella et al. 2004 (SICOG 9909)]
-|rowspan=2|1999-2003
-|rowspan=2 style="background-color:#1a9851"|Phase 3 (E-de-esc)
-|1. [[Non-small_cell_lung_cancer#Gemcitabine_monotherapy|Gemcitabine]]
-|style="background-color:#d3d3d3"|Not reported
-|-
-|2. [[Non-small_cell_lung_cancer#Gemcitabine_.26_Paclitaxel|GT]]<br> 3. [[Non-small_cell_lung_cancer#Gemcitabine_.26_Vinorelbine|GV]]
-| style="background-color:#fc8d59" |Seems to have inferior OS
-|-
-|}
-<div class="toccolours" style="background-color:#b3e2cd">
-====Chemotherapy====
-*[[Paclitaxel (Taxol)]] 100 mg/m<sup>2</sup> IV once per day on days 1, 8, 15
-'''28-day cycle for up to 6 cycles'''
-</div></div><br>
-<div class="toccolours" style="background-color:#eeeeee">
-===Regimen variant #2, 200 mg/m<sup>2</sup> q3wk {{#subobject:5e38ca|Variant=1}}===
-{| class="wikitable sortable" style="width: 100%; text-align:center;"
-!style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
-!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 20%"|Comparator
-!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
-|-
-|[https://academic.oup.com/jnci/article/92/13/1074/2909527 Ranson et al. 2000]
-|1995-1997
-|style="background-color:#1a9851"|Phase 3 (E-esc)
-|[[#Best_supportive_care|Best supportive care]]
-| style="background-color:#91cf60" |Seems to have superior OS
-|-
-|}
-<div class="toccolours" style="background-color:#b3e2cd">
-====Chemotherapy====
-*[[Paclitaxel (Taxol)]] 200 mg/m<sup>2</sup> IV over 3 hours once on day 1
-'''21-day cycles'''
-</div></div>
-===References===
-# Ranson M, Davidson N, Nicolson M, Falk S, Carmichael J, Lopez P, Anderson H, Gustafson N, Jeynes A, Gallant G, Washington T, Thatcher N. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2000 Jul 5;92(13):1074-80. [https://academic.oup.com/jnci/article/92/13/1074/2909527 link to original article] [https://pubmed.ncbi.nlm.nih.gov/10880550 PubMed]
-# '''SICOG 9909:''' Comella P, Frasci G, Carnicelli P, Massidda B, Buzzi F, Filippelli G, Maiorino L, Guida M, Panza N, Mancarella S, Cioffi R. Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients. Br J Cancer. 2004 Aug 2;91(3):489-97. [https://doi.org/10.1038/sj.bjc.6602011 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409832/ link to PMC article]  '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/15266334 PubMed]
-==Vindesine monotherapy {{#subobject:f9f7b9|Regimen=1}}==
-<div class="toccolours" style="background-color:#eeeeee">
-===Regimen {{#subobject:d123895|Variant=1}}===
-{| class="wikitable sortable" style="width: 100%; text-align:center;"
-!style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
-!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 20%"|Comparator
-!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
-|-
-|[https://doi.org/10.1200/JCO.1986.4.7.1037 Einhorn et al. 1986]
-|1982-1984
-|style="background-color:#1a9851"|Phase 3 (C)
-|1. [[#Cisplatin_.26_Vindesine|Cisplatin & Vindesine]]<br>2. [[#MVP_.28Vindesine.29|MVP]]
-|style="background-color:#ffffbf"|Seems not superior
-|-
-|[https://doi.org/10.1093/oxfordjournals.annonc.a010760 Furuse et al. 1996]
-|1991-1993
-|style="background-color:#1a9851"|Phase 3 (C)
-|[[#Vinorelbine_monotherapy|Vinorelbine]]
-| style="background-color:#d73027" |Inferior ORR
-|-
-|}
-<div class="toccolours" style="background-color:#b3e2cd">
-====Chemotherapy====
-*[[Vindesine (Eldisine)]]
-</div></div>
-===References===
-# Einhorn LH, Loehrer PJ, Williams SD, Meyers S, Gabrys T, Nattan SR, Woodburn R, Drasga R, Songer J, Fisher W, Stephens D, Hui S. Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer. J Clin Oncol. 1986 Jul;4(7):1037-43. [https://doi.org/10.1200/JCO.1986.4.7.1037 link to original article] [https://pubmed.ncbi.nlm.nih.gov/3088219 PubMed]
-# Furuse K, Fukuoka M, Kuba M, Yamori S, Nakai Y, Negoro S, Katagami N, Takada Y, Kinuwaki E, Kawahara M, Kubota K, Sakuma A, Niitani H; Japan Vinorelbine Lung Cancer Cooperative Study Group. Randomized study of vinorelbine (VRB) versus vindesine (VDS) in previously untreated stage IIIB or IV non-small-cell lung cancer (NSCLC). Ann Oncol. 1996 Oct;7(8):815-20. [https://doi.org/10.1093/oxfordjournals.annonc.a010760 link to original article] [https://pubmed.ncbi.nlm.nih.gov/8922195 PubMed]
-==Vinorelbine monotherapy {{#subobject:f8gub9|Regimen=1}}==
-<div class="toccolours" style="background-color:#eeeeee">
-===Regimen {{#subobject:dab895|Variant=1}}===
-{| class="wikitable sortable" style="width: 100%; text-align:center;"
-!style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
-!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 20%"|Comparator
-!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
-|-
-|[https://doi.org/10.1200/JCO.1996.14.10.2774 Crawford et al. 1996]
-|1990-1992
-|style="background-color:#1a9851"|Randomized (E-RT-switch-ic)
-|[[#FULV_88|FULV]]
-| style="background-color:#91cf60" |Seems to have superior OS
-|-
-|[https://doi.org/10.1093/oxfordjournals.annonc.a010760 Furuse et al. 1996]
-|1991-1993
-|style="background-color:#1a9851"|Phase 3 (E-switch-ic)
-|[[#Vindesine_monotherapy|Vindesine]]
-| style="background-color:#1a9850" |Superior ORR
 |-
-|}
+|[https://doi.org/10.1002/cncr.28766 Locati et al. 2014 (A4061027)]
-<div class="toccolours" style="background-color:#b3e2cd">
+|2006-2008
-====Chemotherapy====
+| style="background-color:#91cf61" |Phase 2
-*[[Vinorelbine (Navelbine)]]
-</div></div>
-===References===
-# Crawford J, O'Rourke M, Schiller JH, Spiridonidis CH, Yanovich S, Ozer H, Langleben A, Hutchins L, Koletsky A, Clamon G, Burman S, White R, Hohneker J. Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer. J Clin Oncol. 1996 Oct;14(10):2774-84. Erratum in: J Clin Oncol 1996 Dec;14(12):3175. Spiridonitis CH [corrected to Spiridonidis CH]. [https://doi.org/10.1200/JCO.1996.14.10.2774 link to original article] [https://pubmed.ncbi.nlm.nih.gov/8874339 PubMed]
-==VIP {{#subobject:e6f7b9|Regimen=1}}==
-VIP: '''<u>V</u>'''inblastine, '''<u>I</u>'''fosfamide, '''<u>P</u>'''latinol (Cisplatin)
-<div class="toccolours" style="background-color:#eeeeee">
-===Regimen {{#subobject:d00565|Variant=1}}===
-{| class="wikitable sortable" style="width: 100%; text-align:center;"
-!style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
-!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 20%"|Comparator
-!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
-|-
-|[https://doi.org/10.1093/oxfordjournals.annonc.a010642 Kosmidis et al. 1996a]
-|1992-1994
-|style="background-color:#1a9851"|Phase 3 (C)
-|[[#VIP-16_99|VIP-16]]
-|style="background-color:#ffffbf"|Seems not superior
 |-
 |}
-<div class="toccolours" style="background-color:#b3e2cd">
-====Chemotherapy====
-*[[Vinblastine (Velban)]]
-*[[Ifosfamide (Ifex)]]
-*[[Cisplatin (Platinol)]]
-</div></div>
-===References===
-# Kosmidis P, Mylonakis N, Fountzilas G, Pavlidis N, Samantas E, Karabelis A, Kattis K, Skarlos D; HeCOG. A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfamide, vinblastine (VIP) versus cisplatin, ifosfamide and etoposide (VIP-16). Ann Oncol. 1996 Jul;7(5):517-20. [https://doi.org/10.1093/oxfordjournals.annonc.a010642 link to original article] [https://pubmed.ncbi.nlm.nih.gov/8839908 PubMed]
-=Maintenance after first-line therapy=
-==Erlotinib monotherapy {{#subobject:096cdf|Regimen=1}}==
-<div class="toccolours" style="background-color:#eeeeee">
-===Regimen {{#subobject:16398e|Variant=1}}===
-{| class="wikitable sortable" style="width: 100%; text-align:center;"
-!style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
-!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 20%"|Comparator
-!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
-|-
-|[https://doi.org/10.1016/S1470-2045(10)70112-1 Cappuzzo et al. 2010 (SATURN)]
-|2005-2008
-|style="background-color:#1a9851"|Phase 3 (E-RT-esc)
-|[[Non-small_cell_lung_cancer#Placebo_4|Placebo]]
-|style="background-color:#1a9850"|Superior PFS
-|-
-|rowspan=2|[https://doi.org/10.1200/JCO.2011.39.9782 Pérol et al. 2012 (IFCT-GFPC 0502)]
-|rowspan=2|2006-2009
-|rowspan=2 style="background-color:#1a9851"|Phase 3 (E-esc)
-|1. [[Non-small_cell_lung_cancer#Gemcitabine_monotherapy_2|Gemcitabine]]
-|style="background-color:#d3d3d3"|Not reported
-|-
-|2. [[Non-small_cell_lung_cancer#Observation_3|Observation]]
-|style="background-color:#1a9850"|Superior PFS
-|-
-|[https://doi.org/10.1016/j.lungcan.2016.10.007 Cicènas et al. 2016 (IUNO)]
-|2011-2014
-|style="background-color:#1a9851"|Phase 3 (E-RT-switch-ic)
-|[[Complex_multipart_regimens#IUNO|See link]]
-| style="background-color:#ffffbf" |[[Complex_multipart_regimens#IUNO|See link]]
-|-
-|}
-''Note: while SATURN was technically a positive study for erlotinib, the median PFS gain was 1.2 weeks. This study was the basis of an FDA approval in 2010, which was later revised after the results of IUNO became available. The trials included here did not require EGFR mutation as a condition for enrollment.''
-<div class="toccolours" style="background-color:#cbd5e8">
-====Preceding treatment====
-*SATURN and IUNO: [[Regimen_classes#Platinum_doublet|Platinum-doublet therapy]] x 4
-*IFCT-GFPC 0502: [[Non-small_cell_lung_cancer#Cisplatin_.26_Gemcitabine_.28GC.29_3|Cisplatin & Gemcitabine]] x 4
-</div>
 <div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
-*[[Erlotinib (Tarceva)]] 150 mg PO once per day
+*[[Axitinib (Inlyta)]] 5 mg PO twice per day
 '''Continued indefinitely'''
 </div></div>
 ===References===
-# '''SATURN:''' Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, Esteban E, Molinier O, Brugger W, Melezínek I, Klingelschmitt G, Klughammer B, Giaccone G; SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010 Jun;11(6):521-9. Epub 2010 May 20. [https://doi.org/10.1016/S1470-2045(10)70112-1 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/20493771 PubMed] NCT00556712
+# '''A4061027:''' Locati LD, Licitra L, Agate L, Ou SH, Boucher A, Jarzab B, Qin S, Kane MA, Wirth LJ, Chen C, Kim S, Ingrosso A, Pithavala YK, Bycott P, Cohen EE. Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments. Cancer. 2014 Sep 1;120(17):2694-703. Epub 2014 May 20. [https://doi.org/10.1002/cncr.28766 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/24844950 PubMed] NCT00389441
-# '''IFCT-GFPC 0502:''' Pérol M, Chouaid C, Pérol D, Barlési F, Gervais R, Westeel V, Crequit J, Léna H, Vergnenègre A, Zalcman G, Monnet I, Le Caer H, Fournel P, Falchero L, Poudenx M, Vaylet F, Ségura-Ferlay C, Devouassoux-Shisheboran M, Taron M, Milleron B. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2012 Oct 1;30(28):3516-24. Epub 2012 Sep 4. [https://doi.org/10.1200/JCO.2011.39.9782 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/22949150 PubMed] NCT00300586
+==Sunitinib monotherapy {{#subobject:8d6c5|Regimen=1}}==
-# '''IUNO:''' Cicènas S, Geater SL, Petrov P, Hotko Y, Hooper G, Xia F, Mudie N, Wu YL. Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study). Lung Cancer. 2016 Dec;102:30-37. Epub 2016 Oct 20. [https://doi.org/10.1016/j.lungcan.2016.10.007 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/27987585 PubMed] NCT01328951
-=Advanced or metastatic disease, subsequent lines of therapy=
-==Erlotinib monotherapy {{#subobject:c3c726|Regimen=1}}==
 <div class="toccolours" style="background-color:#eeeeee">
-===Regimen {{#subobject:d27efc|Variant=1}}===
+===Regimen {{#subobject:d1cea4|Variant=1}}===
-{| class="wikitable sortable" style="width: 100%; text-align:center;"
+{| class="wikitable sortable" style="width: 80%; text-align:center;"
-!style="width: 20%"|Study
+!style="width: 25%"|Study
-!style="width: 20%"|Years of enrollment
+!style="width: 25%"|Years of enrollment
-!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 20%"|Comparator
+!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
-!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 |-
-|[https://doi.org/10.1056/NEJMoa050753 Shepherd et al. 2005 (NCIC-CTG BR.21)]
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3063514/ Carr et al. 2010]
-|2001-2003
-|style="background-color:#1a9851"|Phase 3 (E-RT-esc)
-|[[Non-small_cell_lung_cancer#Placebo_4|Placebo]]
-|style="background-color:#1a9850"|Superior OS<br>Median OS: 6.7 vs 4.7 mo<br>(aHR 0.70, 95% CI 0.58-0.85)
-|-
-|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134127/ Herbst et al. 2011 (BeTa)]
-|2005-2008
-|style="background-color:#1a9851"|Phase 3 (C)
-|[[#Erlotinib_.26_Bevacizumab_99|Erlotinib & Bevacizumab]]
-|style="background-color:#ffffbf"|Did not meet primary endpoint of OS
-|-
-|[https://doi.org/10.1200/JCO.2010.28.5981 Natale et al. 2011 (ZEST)]
-|2006-2007
-|style="background-color:#1a9851"|Phase 3 (C)
-|[[#Vandetanib_monotherapy_99|Vandetanib]]
-|style="background-color:#ffffbf"|Did not meet primary endpoint of PFS
-|-
-|[https://doi.org/10.1016/S1470-2045(11)70385-0 Ciuleanu et al. 2012 (TITAN)]
-|2006-2010
-|style="background-color:#1a9851"|Phase 3 (E-switch-ooc)
-|Investigator's choice of:<br>1a. [[Non-small_cell_lung_cancer#Docetaxel_monotherapy_3|Docetaxel]]<br>1b. [[Non-small_cell_lung_cancer#Pemetrexed_monotherapy_3|Pemetrexed]]
-|style="background-color:#ffffbf"|Did not meet primary endpoint of OS
-|-
-|[https://doi.org/10.1002/cncr.28132 Karampeazis et al. 2013 (CT/06.05)]
-|2006-2010
-|style="background-color:#1a9851"|Phase 3 (E-switch-ooc)
-|[[Non-small_cell_lung_cancer#Pemetrexed_monotherapy_3|Pemetrexed]]
-|style="background-color:#ffffbf"|Did not meet primary endpoint of TTP
-|-
-|[https://doi.org/10.1200/JCO.2011.39.2993 Scagliotti et al. 2012 (SUN 1087)]
 |2007-2009
-|style="background-color:#1a9851"|Phase 3 (C)
+| style="background-color:#91cf61" |Phase 2
-|[[Stub#Erlotinib_.26_Sunitinib|Erlotinib & Sunitinib]]
+|ORR: 31% (95% CI: 16-47)
-|style="background-color:#ffffbf"|Did not meet primary endpoint of OS
-|-
-|[https://doi.org/10.1016/S1470-2045(13)70310-3 Garassino et al. 2013 (TAILOR<sub>NSCLC</sub>)]
-|2007-2012
-|style="background-color:#1a9851"|Phase 3 (E-switch-ooc)
-|[[Non-small_cell_lung_cancer#Docetaxel_monotherapy_3|Docetaxel]]
-|style="background-color:#fc8d59"|Seems to have inferior OS
-|-
-|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321098/ Ramalingam et al. 2012 (A7471028)]
-|2008-2009
-|style="background-color:#1a9851"|Randomized Phase 2 (C)
-|[[#Dacomitinib_monotherapy_99|Dacomitinib]]
-|style="background-color:#fc8d59"|Seems to have inferior PFS
-|-
-|[https://doi.org/10.1093/annonc/mdu517 Scagliotti et al. 2015 (ADVIGO 1018)]
-|2008-2010
-|style="background-color:#1a9851"|Phase 3 (C)
-|[[Stub#Erlotinib_.26_Figitumumab|Erlotinib & Figitumumab]]
-|style="background-color:#ffffbf"|Did not meet primary endpoint of OS
-|-
-|[https://doi.org/10.1200/JCO.2013.52.4694 Kawaguchi et al. 2014 (DELTA<sub>NSCLC</sub>)]
-|2009-2012
-|style="background-color:#1a9851"|Phase 3 (E-switch-ooc)
-|[[Non-small_cell_lung_cancer#Docetaxel_monotherapy_3|Docetaxel]]
-| style="background-color:#fee08b" |Might have inferior PFS
-|-
-|[https://doi.org/10.1200/jco.2015.63.4154 Urata et al. 2016 (WJOG 5108L)]
-|2009-2012
-|style="background-color:#1a9851"|Phase 3 (C)
-|[[Non-small_cell_lung_cancer#Gefitinib_monotherapy_2|Gefitinib]]
-|style="background-color:#ffffbf"|Inconclusive whether non-inferior PFS
-|-
-|[https://doi.org/10.1016/j.lungcan.2016.06.019 Smit et al. 2016 (CurrentS)]
-|2010-NR
-|style="background-color:#1a9851"|Phase 3 (C)
-|[[#Erlotinib_monotherapy_2|Erlotinib]]; high-dose
-|style="background-color:#ffffbf"|Did not meet primary endpoint of PFS
-|-
-|[https://doi.org/10.1016/j.biopha.2017.02.097 Wang et al. 2017a]
-|2010-2014
-|style="background-color:#1a9851"|Phase 3 (C)
-|[[#Erlotinib.2C_Bevacizumab.2C_Panitumumab_88|Erlotinib, Bevacizumab, Panitumumab]]
-|style="background-color:#fc8d59"|Seems to have inferior OS
-|-
-|[https://doi.org/10.1093/annonc/mdv288 Yoshioka et al. 2015 (ATTENTION)]
-|2011-2012
-|style="background-color:#1a9851"|Phase 3 (C)
-|[[Stub#Erlotinib_.26_Tivantinib|Erlotinib & Tivantinib]]
-|style="background-color:#ffffbf"|Did not meet primary endpoint of OS
-|-
-|[https://doi.org/10.1200/JCO.2014.60.7317 Scagliotti et al. 2015 (MARQUEE)]
-|2011-2012
-|style="background-color:#1a9851"|Phase 3 (C)
-|[[Stub#Erlotinib_.26_Tivantinib|Erlotinib & Tivantinib]]
-|style="background-color:#ffffbf"|Did not meet primary endpoint of OS
-|-
-|[https://doi.org/10.1016/S1470-2045(14)70452-8 Ramalingam et al. 2014 (ARCHER 1009)]
-|2011-2013
-|style="background-color:#1a9851"|Phase 3 (C)
-|[[#Dacomitinib_monotherapy_99|Dacomitinib]]
-|style="background-color:#ffffbf"|Did not meet primary endpoint of PFS
-|-
-|[https://doi.org/10.1016/j.lungcan.2016.10.007 Cicènas et al. 2016 (IUNO)]
-|2011-2014
-|style="background-color:#1a9851"|Phase 3 (C)
-|[[Complex_multipart_regimens#IUNO|See link]]
-|style="background-color:#ffffbf"|[[Complex_multipart_regimens#IUNO|See link]]
-|-
-|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440713 Gridelli et al. 2018 (AvaALL)]
-|2011-2015
-|style="background-color:#1a9851"|Phase 3 (C)
-|Investigator's choice of:<br>1a. [[#Docetaxel_.26_Bevacizumab_99|Docetaxel & Bevacizumab]]<br>1b. [[#Erlotinib_.26_Bevacizumab_99|Erlotinib & Bevacizumab]]<br>1c. [[#Pemetrexed_.26_Bevacizumab_99|Pemetrexed & Bevacizumab]]
-|style="background-color:#ffffbf"|Did not meet primary endpoint of OS
-|-
-|[https://doi.org/10.1200/JCO.2016.69.2160 Spigel et al. 2016 (METLung)]
-|2012-2013
-|style="background-color:#1a9851"|Phase 3 (C)
-|[[Stub#Erlotinib_.26_Onartuzumab|Erlotinib & Onartuzumab]]
-|style="background-color:#d9ef8b"|Might have superior OS
-|-
-|[https://doi.org/10.1016/S1470-2045(15)00006-6 Soria et al. 2015 (LUX-Lung 8)]
-|2012-2014
-|style="background-color:#1a9851"|Phase 3 (C)
-|[[Non-small_cell_lung_cancer#Afatinib_monotherapy|Afatinib]]
-| style="background-color:#fc8d59" |Seems to have inferior OS<sup>1</sup>
-|-
-|rowspan=2|[https://doi.org/10.1016/S1470-2045(16)30561-7 Neal et al. 2016 (ECOG-ACRIN 1512)]
-|rowspan=2|2013-2014
-|rowspan=2 style="background-color:#1a9851"|Randomized Phase 2 (C)
-|1. [[Non-small_cell_lung_cancer#Cabozantinib_monotherapy|Cabozantinib]]
-|style="background-color:#d73027"|Inferior PFS
-|-
-|2. [[Non-small_cell_lung_cancer#Cabozantinib_.26_Erlotinib|Cabozantinib & Erlotinib]]
-|style="background-color:#d73027"|Inferior PFS
-|-
-|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7649422/ Goldman et al. 2020 (JUNIPER)]
-|2014-2017
-|style="background-color:#1a9851"|Phase 3 (C)
-|[[#Abemaciclib_monotherapy_99|Abemaciclib]]
-|style="background-color:#ffffbf"|Did not meet primary endpoint of OS
 |-
 |}
-''<sup>1</sup>Reported efficacy is based on the 2021 update.''<br>
-''Note: the trials included here did not require EGFR mutation as a condition for enrollment. Given the FDA limitation on use in this setting issued in 2016, these regimens have been moved to the historical page. Note that there is another trial named TAILOR in colorectal cancer and another trial named DELTA in indolent lymphoma.''
-<div class="toccolours" style="background-color:#fdcdac">
-====Biomarker eligibility criteria====
-*JUNIPER: KRAS G12 or G13 mutation
-</div>
-<div class="toccolours" style="background-color:#cbd5e8">
-====Preceding treatment====
-*IUNO: [[Non-small_cell_lung_cancer#Placebo_4|Placebo]]
-</div>
 <div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
-*[[Erlotinib (Tarceva)]] 150 mg PO once per day
+*[[Sunitinib (Sutent)]] 37.5 mg PO once per day
 '''Continued indefinitely'''
 </div></div>
 ===References===
-# '''NCIC-CTG BR.21:''' Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005 Jul 14;353(2):123-32. [https://doi.org/10.1056/NEJMoa050753 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/16014882 PubMed] NCT00036647
+# Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010 Nov 1;16(21):5260-8. Epub 2010 Sep 16. [https://doi.org/10.1158/1078-0432.CCR-10-0994 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3063514/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/20847059 PubMed]
-<!-- Presented at the 45th Annual Meeting of the American Society of Clinical Oncology, May 29-June 2, 2009, Orlando, FL; 13th Annual World Congress on Lung Cancer, July 31-August 4, 2009, San Francisco, CA; and Joint 15th Congress of the European Cancer Organisation and 34th Congress of the European Society for Medical Oncology, September 20-24, 2009, Berlin, Germany. -->
+[[Category:Thyroid cancer regimens]]
-# '''ZEST:''' Natale RB, Thongprasert S, Greco FA, Thomas M, Tsai CM, Sunpaweravong P, Ferry D, Mulatero C, Whorf R, Thompson J, Barlesi F, Langmuir P, Gogov S, Rowbottom JA, Goss GD. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2011 Mar 10;29(8):1059-66. Epub 2011 Jan 31. [https://doi.org/10.1200/JCO.2010.28.5981 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/21282542 PubMed] NCT00364351
-## '''Dataset:''' [https://www.projectdatasphere.org/projectdatasphere/html/content/164 Project Data Sphere]
-# '''BeTa:''' Herbst RS, Ansari R, Bustin F, Flynn P, Hart L, Otterson GA, Vlahovic G, Soh CH, O'Connor P, Hainsworth J. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet. 2011 May 28;377(9780):1846-54. [https://doi.org/10.1016/S0140-6736(11)60545-X link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134127/ link to PMC article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/21621716 PubMed] NCT00130728
-# '''TITAN:''' Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C, Johannsdottir HK, Klughammer B, Gonzalez EE. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol. 2012 Mar;13(3):300-8. Epub 2012 Jan 24. [https://doi.org/10.1016/S1470-2045(11)70385-0 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/22277837 PubMed] NCT00556322
-<!-- Presented previously, in part, at the European Society for Medical Oncology Congress, Milan, Italy, October 8-12, 2010; Asia-Pacific Lung Cancer Conference, Seoul, Korea, December 2-4, 2010; and the Chicago Multidisciplinary Symposium in Thoracic Oncology, Chicago, IL, December 9-11, 2010. -->
-# '''SUN 1087:''' Scagliotti GV, Krzakowski M, Szczesna A, Strausz J, Makhson A, Reck M, Wierzbicki RF, Albert I, Thomas M, Miziara JE, Papai ZS, Karaseva N, Thongprasert S, Portulas ED, von Pawel J, Zhang K, Selaru P, Tye L, Chao RC, Govindan R. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. J Clin Oncol. 2012 Jun 10;30(17):2070-8. Epub 2012 May 7. [https://doi.org/10.1200/JCO.2011.39.2993 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/22564989 PubMed] NCT00457392
-<!-- Presented in part at the 46th Annual Meeting of the American Society of Clinical Oncology, June 4-8, 2010, Chicago, IL; the 35th Congress of the European Society for Medical Oncology, October 8-12, 2010, Milan, Italy; and the 14th World Conference on Lung Cancer, July 3-7, 2011, Amsterdam, the Netherlands. -->
-# '''A7471028:''' Ramalingam SS, Blackhall F, Krzakowski M, Barrios CH, Park K, Bover I, Seog Heo D, Rosell R, Talbot DC, Frank R, Letrent SP, Ruiz-Garcia A, Taylor I, Liang JQ, Campbell AK, O'Connell J, Boyer M. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2012 Sep 20;30(27):3337-44. Epub 2012 Jul 2. [https://doi.org/10.1200/JCO.2011.40.9433 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321098/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/22753918 PubMed] NCT00769067
-# '''CT/06.05:''' Karampeazis A, Voutsina A, Souglakos J, Kentepozidis N, Giassas S, Christofillakis C, Kotsakis A, Papakotoulas P, Rapti A, Agelidou M, Agelaki S, Vamvakas L, Samonis G, Mavroudis D, Georgoulias V; Hellenic Oncology Research Group. Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study. Cancer. 2013 Aug 1;119(15):2754-64. Epub 2013 May 9. [https://doi.org/10.1002/cncr.28132 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/23661337 PubMed] NCT00440414
-# '''TAILOR<sub>NSCLC</sub>:''' Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, Bianchi F, Bettini A, Longo F, Moscetti L, Tomirotti M, Marabese M, Ganzinelli M, Lauricella C, Labianca R, Floriani I, Giaccone G, Torri V, Scanni A, Marsoni S; TAILOR trialists. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 2013 Sep;14(10):981-8. Epub 2013 Jul 22. [https://doi.org/10.1016/S1470-2045(13)70310-3 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/23883922 PubMed] NCT00637910
-# '''DELTA<sub>NSCLC</sub>:''' Kawaguchi T, Ando M, Asami K, Okano Y, Fukuda M, Nakagawa H, Ibata H, Kozuki T, Endo T, Tamura A, Kamimura M, Sakamoto K, Yoshimi M, Soejima Y, Tomizawa Y, Isa S, Takada M, Saka H, Kubo A. Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). J Clin Oncol. 2014 Jun 20;32(18):1902-8. Epub 2014 May 19. [https://doi.org/10.1200/JCO.2013.52.4694 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/24841974 PubMed]
-# '''ARCHER 1009:''' Ramalingam SS, Jänne PA, Mok T, O'Byrne K, Boyer MJ, Von Pawel J, Pluzanski A, Shtivelband M, Docampo LI, Bennouna J, Zhang H, Liang JQ, Doherty JP, Taylor I, Mather CB, Goldberg Z, O'Connell J, Paz-Ares L. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014 Nov;15(12):1369-78. Epub 2014 Oct 15.[https://doi.org/10.1016/S1470-2045(14)70452-8 link to original article] [https://pubmed.ncbi.nlm.nih.gov/25439691 PubMed] NCT01360554
-# '''ADVIGO 1018:''' Scagliotti GV, Bondarenko I, Blackhall F, Barlesi F, Hsia TC, Jassem J, Milanowski J, Popat S, Sanchez-Torres JM, Novello S, Benner RJ, Green S, Molpus K, Soria JC, Shepherd FA. Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer. Ann Oncol. 2015 Mar;26(3):497-504. Epub 2014 Nov 13. [https://doi.org/10.1093/annonc/mdu517 link to original article] [https://pubmed.ncbi.nlm.nih.gov/25395283 PubMed] NCT00673049
-# '''LUX-Lung 8:''' Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Isla D, Guclu SZ, Morabito A, Min YJ, Ardizzoni A, Gadgeel SM, Wang B, Chand VK, Goss GD; LUX-Lung 8 Investigators. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2015 Aug;16(8):897-907. Epub 2015 Jul 5. [https://doi.org/10.1016/S1470-2045(15)00006-6 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/26156651 PubMed] NCT01523587
-##'''Update:''' Goss GD, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Isla D, Morabito A, Min YJ, Ardizzoni A, Bender S, Cseh A, Felip E. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial. EClinicalMedicine. 2021 Jun 18;37:100940. [https://doi.org/10.1016/j.eclinm.2021.100940 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8225678/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/34195574/ PubMed]
-# '''ATTENTION:''' Yoshioka H, Azuma K, Yamamoto N, Takahashi T, Nishio M, Katakami N, Ahn MJ, Hirashima T, Maemondo M, Kim SW, Kurosaki M, Akinaga S, Park K, Tsai CM, Tamura T, Mitsudomi T, Nakagawa K. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study). Ann Oncol. 2015 Oct;26(10):2066-72. Epub 2015 Jul 7. [https://doi.org/10.1093/annonc/mdv288 link to original article] [https://pubmed.ncbi.nlm.nih.gov/26153496 PubMed] NCT01377376
-# '''MARQUEE:''' Scagliotti G, von Pawel J, Novello S, Ramlau R, Favaretto A, Barlesi F, Akerley W, Orlov S, Santoro A, Spigel D, Hirsh V, Shepherd FA, Sequist LV, Sandler A, Ross JS, Wang Q, von Roemeling R, Shuster D, Schwartz B. Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol. 2015 Aug 20;33(24):2667-74. Epub 2015 Jul 13. [https://doi.org/10.1200/JCO.2014.60.7317 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/26169611 PubMed] NCT01244191
-# '''WJOG 5108L:''' Urata Y, Katakami N, Morita S, Kaji R, Yoshioka H, Seto T, Satouchi M, Iwamoto Y, Kanehara M, Fujimoto D, Ikeda N, Murakami H, Daga H, Oguri T, Goto I, Imamura F, Sugawara S, Saka H, Nogami N, Negoro S, Nakagawa K, Nakanishi Y. Randomized phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L. J Clin Oncol. 2016 Sep 20;34(27):3248-57. Epub 2016 Mar 28. [https://doi.org/10.1200/jco.2015.63.4154 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/27022112 PubMed] UMIN000002014
-# '''CurrentS:''' Smit EF, Wu YL, Gervais R, Zhou C, Felip E, Feng J, Guclu SZ, Hoiczyk M, Dorokhova E, Freudensprung U, Grange S, Perez-Moreno PD, Mitchell L, Reck M. A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS). Lung Cancer. 2016 Sep;99:94-101. Epub 2016 Jun 27. [https://doi.org/10.1016/j.lungcan.2016.06.019 link to original article] [https://pubmed.ncbi.nlm.nih.gov/27565921 PubMed] NCT01183858
-# '''IUNO:''' Cicènas S, Geater SL, Petrov P, Hotko Y, Hooper G, Xia F, Mudie N, Wu YL. Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study). Lung Cancer. 2016 Dec;102:30-37. Epub 2016 Oct 20. [https://doi.org/10.1016/j.lungcan.2016.10.007 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/27987585 PubMed] NCT01328951
-# '''ECOG-ACRIN 1512:''' Neal JW, Dahlberg SE, Wakelee HA, Aisner SC, Bowden M, Huang Y, Carbone DP, Gerstner GJ, Lerner RE, Rubin JL, Owonikoko TK, Stella PJ, Steen PD, Khalid AA, Ramalingam SS; ECOG-ACRIN. Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol. 2016 Dec;17(12):1661-1671. Epub 2016 Nov 4. [https://doi.org/10.1016/S1470-2045(16)30561-7 link to original article] '''contains dosing details in abstract''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5154681/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27825638 PubMed] NCT01708954
-# '''METLung:''' Spigel DR, Edelman MJ, O'Byrne K, Paz-Ares L, Mocci S, Phan S, Shames DS, Smith D, Yu W, Paton VE, Mok T. Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: METLung. J Clin Oncol. 2017 Feb;35(4):412-420. Epub 2016 Dec 12. [https://doi.org/10.1200/JCO.2016.69.2160 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/27937096 PubMed] NCT01456325
-# Wang Y, Wang H, Jiang Y, Zhang Y, Wang X. A randomized phase III study of combining erlotinib with bevacizumab and panitumumab versus erlotinib alone as second-line therapy for Chinese patients with non-small-cell lung cancer. Biomed Pharmacother. 2017 May;89:875-879. Epub 2017 Mar 6. [https://doi.org/10.1016/j.biopha.2017.02.097 link to original article] [https://pubmed.ncbi.nlm.nih.gov/28282789 PubMed]
-# '''AvaALL:''' Gridelli C, de Castro Carpeno J, Dingemans AC, Griesinger F, Grossi F, Langer C, Ohe Y, Syrigos K, Thatcher N, Das-Gupta A, Truman M, Donica M, Smoljanovic V, Bennouna J. Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial. JAMA Oncol. 2018 Dec 1;4(12):e183486. Epub 2018 Dec 13. Erratum in: JAMA Oncol. 2018 Dec 1;4(12):1792. [https://jamanetwork.com/journals/jamaoncology/article-abstract/2698039 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440713 link to PMC article] '''contains dosing details in supplement''' [https://pubmed.ncbi.nlm.nih.gov/30177994 PubMed] NCT01351415
-# '''JUNIPER:''' Goldman JW, Mazieres J, Barlesi F, Dragnev KH, Koczywas M, Göskel T, Cortot AB, Girard N, Wesseler C, Bischoff H, Nadal E, Park K, Lu S, Taus A, Cobo M, Estrem ST, Wijayawardana SR, Turner K, Oakley GJ 3rd, Hurt KC, Chiang AY, Hossain AM, John WJ, Paz-Ares L. A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER. Front Oncol. 2020 Oct 26;10:578756. [https://doi.org/10.3389/fonc.2020.578756 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7649422/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/33194700/ PubMed] NCT02152631
-[[Category:Non-small cell lung cancer regimens]]
-[[Category:Historical regimens]]
 [[Category:Disease-specific pages]]
-[[Category:Lung cancers]]
+[[Category:Endocrine cancers]]
+[[Category:Head and neck cancers]]

Difference between revisions of "Staging page"

Revision as of 23:40, 9 February 2023

Guidelines

ATA

ESMO

Older

NCCN

All lines of therapy

Cabozantinib monotherapy

Regimen

Targeted therapy

References

Placebo

Regimen

References

Sorafenib monotherapy

Regimen

Targeted therapy

References

Sunitinib monotherapy

Regimen

Targeted therapy

References

Vandetanib monotherapy

Regimen variant #1, 100 mg/day

Targeted therapy

Subsequent treatment

Regimen variant #2, 300 mg/day

Targeted therapy

References

Advanced or metastatic disease

Axitinib monotherapy

Regimen

Targeted therapy

References

Sunitinib monotherapy

Regimen

Targeted therapy

References

Navigation menu

Search